Generation and Characterization of Functional Human Hypothalamic Neurons. by Kirwan, Peter et al.
Generation	  and	  characterisation	  of	  functional	  human	  hypothalamic	  neurons	  
	  
Peter	  Kirwan1,2,	  Magdalena	  Jura1,2,	  Florian	  T.	  Merkle1,2*	  
	  
1.   Metabolic	   Research	   Laboratories	   and	   Medical	   Research	   Council	   Metabolic	   Diseases	   Unit,	  
Wellcome	   Trust-­‐Medical	   Research	   Council	   Institute	   of	   Metabolic	   Science,	   University	   of	  
Cambridge,	  Cambridge,	  CB2	  0QQ,	  UK	  
2.   The	  Anne	  McLaren	  Laboratory,	  Wellcome	  Trust-­‐Medical	  Research	  Council	  Cambridge	  Stem	  Cell	  
Institute,	  University	  of	  Cambridge,	  Cambridge,	  CB2	  0SZ,	  UK	  
	  
*To	  whom	  correspondence	  should	  be	  addressed	  
fm436@medschl.cam.ac.uk	  
WT-­‐MRC	  Institute	  of	  Metabolic	  Science	  (Level	  4)	  
Addenbrooke’s	  Site	  (B289),	  Keith	  Day	  Road	  
Cambridge,	  CB2	  0QQ,	  UK	  
Phone:	  +44	  (0)1223	  747490	  
	  
	   	  
Significance	  statement:	  
Since	  many	   human	   diseases	   stem	   from	   the	   loss	   or	   dysfunction	   of	   hypothalamic	   neurons,	   in	   vitro	  
disease	   models	   built	   around	   human	   stem	   cell-­‐derived	   hypothalamic	   neurons	   are	   a	   potentially	  
powerful	  tool	  to	  understand	  molecular	  and	  cellular	  disease	  mechanisms.	  The	  protocols	  described	  here	  
aim	  to	  enable	  groups	  to	  interrogate	  the	  functions	  of	  human	  hypothalamic	  neurons.	  	  
	  
Abstract:	  
Neurons	   in	   the	   hypothalamus	   orchestrate	   homeostatic	   physiological	   processes	   and	   behaviours	  
essential	   for	   life.	   Defects	   in	   the	   function	   of	   hypothalamic	   neurons	   cause	   a	   spectrum	   of	   human	  
diseases,	   including	   obesity,	   infertility,	   growth	   defects,	   sleep	   disorders,	   social	   disorders,	   and	   stress	  
disorders.	  These	  diseases	  have	  been	  studied	  in	  animal	  models	  such	  as	  mice,	  but	  the	  rarity	  and	  relative	  
inaccessibility	  of	  mouse	  hypothalamic	  neurons,	  and	  species-­‐specific	  differences	  between	  mice	  and	  
humans	  highlight	  the	  need	  for	  human	  cellular	  models	  of	  hypothalamic	  diseases.	  We	  and	  others	  have	  
developed	  methods	  to	  differentiate	  human	  pluripotent	  stem	  cells	  (hPSCs)	  into	  hypothalamic	  neurons	  
and	   related	   cell	   types,	   such	   as	   astrocytes.	   This	   protocol	   builds	   on	   published	   studies	   by	   providing	  
detailed	   step-­‐by-­‐step	   instructions	   for	   neuronal	   differentiation,	   quality	   control,	   long-­‐term	  neuronal	  
maintenance,	  and	  the	  functional	   interrogation	  of	  hypothalamic	  cells	  by	  calcium	  imaging.	  Together,	  
these	  protocols	   should	   enable	   any	   group	  with	   appropriate	   facilities	   to	   generate	   and	   study	  human	  
hypothalamic	  cells.	  
	  




The	   hypothalamus	   is	   highly	   conserved	   brain	   region	   responsible	   for	   a	   wide	   array	   of	  
homeostatic	  processes	  (Swaab	  et	  al.,	  1993).	  Distinct	  hypothalamic	  functions	  are	  controlled	  by	  unique	  
neuronal	  cell	  types,	  often	  via	  neuropeptides	  that	  have	  potent	  effects	  on	  behaviour	  and	  physiology.	  
For	   example,	   neurons	   producing	   the	   melanocortins	   agouti-­‐related	   peptide	   (AGRP),	   or	   pro-­‐
opiomelanocortin	   (POMC),	  potently	  stimulate	  or	   inhibit	   feeding	  behaviour,	   respectively	   (Fan	  et	  al.,	  
1997;	   Ollmann	   et	   al.,	   1997;	   Cone,	   2006;	   Zhan	   et	   al.,	   2013).	   Neurons	   that	   produce	   corticotropin	  
releasing	   hormone	   (CRH)	   sit	   at	   the	   apex	   of	   the	   hypothalamic-­‐pituitary-­‐adrenal	   (HPA)	   axis	   that	  
regulates	  stress	  responses	  (Zoumakis	  and	  Chrousos,	  2010;	  Aguilera	  and	  Liu,	  2012),	  and	  neurons	  that	  
produce	  thyrotropin	  releasing	  hormone	  (TRH)	  regulate	  energy	  expenditure	  by	  affecting	  the	  activity	  of	  
the	   thyroid	   gland	   (Hollenberg,	   2008;	   Lechan	   and	   Fekete,	   2006).	   Melanin	   concentrating	   hormone	  
(MCH)	   is	   a	   neuropeptide	   produced	   by	   hypothalamic	   neurons	   that	   regulate	   sleep	   and	  metabolism	  
(Konadhode	   et	   al.,	   2013;	   Qu	   et	   al.,	   1996;	   Ferreira	   et	   al.,	   2017),	   and	   neurons	   producing	  
hypocretin/orexin	  (HCRT)	  are	  essential	  for	  normal	  sleep	  regulation	  and	  are	  lost	  in	  the	  sleep	  disorder	  
narcolepsy	  (Nixon	  et	  al.,	  2015;	  Thannickal	  et	  al.,	  2000;	  Peyron	  et	  al.,	  2000).	  There	  is	  a	  pressing	  need	  to	  
better	   understand	   how	   the	   abnormal	   function	   of	   hypothalamic	   neurons	   contributes	   to	   human	  
disease.	  For	  example,	  obesity,	  thought	  to	  be	  largely	  a	  disease	  of	  the	  brain,	  affects	  approximately	  one	  
third	  of	  adults	  in	  Western	  countries,	  and	  significantly	  decreases	  lifespan	  (Ng	  et	  al.,	  2014;	  Locke	  et	  al.,	  
2015).	  	  
To	  enable	  the	  study	  of	  live,	  human	  hypothalamic	  neurons,	  we	  (Merkle	  et	  al.,	  2015)	  and	  others	  
(Wang	  et	  al.,	  2015)	  developed	  protocols	  to	  differentiate	  hPSCs,	  including	  human	  embryonic	  stem	  cells	  
(hESCs)	   and	   human	   induced	   pluripotent	   stem	   cells	   (hiPSCs),	   into	   hypothalamic	   neurons.	   These	  
differentiation	  protocols	  were	  designed	  by	  applying	  knowledge	  of	  the	  signalling	  pathways	  known	  to	  
pattern	  the	  developing	  ventral	  forebrain	  (Puelles	  and	  Rubenstein,	  2003;	  Sussel	  et	  al.,	  1999),	  and	  by	  
building	   upon	   previously	   established	   neuronal	   directed	   differentiation	   protocols	   (Chambers	   et	   al.,	  
2009;	  Maroof	  et	  al.,	  2013;	  Shi	  et	  al.,	  2012).	  	  
Human	  stem	  cell-­‐derived	  hypothalamic	  neurons	  recapitulate	  many	  of	  the	  essential	  properties	  
of	  their	  counterparts	  in	  vivo	  (Merkle	  et	  al.,	  2015;	  Wang	  et	  al.,	  2015,	  2017;	  Yamada-­‐Goto	  et	  al.,	  2017),	  
making	  them	  an	  excellent	  scientific	  model	  for	  a	  number	  of	  reasons.	  First,	  hPSCs	  and	  their	  derivatives	  
have	  diploid	  genomes	  broadly	  representative	  of	  those	  found	  in	  human	  populations	  (Adewumi	  et	  al.,	  
2007;	  Amps	  et	  al.,	  2011;	  Thomson	  et	  al.,	  1998),	  an	  essential	  consideration	  when	  seeking	  to	  model	  the	  
effect	   of	   human	   genetic	   variants	   on	   cellular	   phenotypes.	   The	   ability	   to	   readily	  modify	   the	   human	  
genome	  using	  CRISPR/Cas9	  and	  other	  gene	  editing	  tools	  facilitates	  the	  generation	  of	  reporter	  cell	  lines	  
to	  study	  cell	  types	  of	  interest	  and	  to	  generate	  isogenic	  disease	  models	  (Ran	  et	  al.,	  2013;	  Merkle	  and	  
Eggan,	   2013;	   Hendriks	   et	   al.,	   2016;	   Hockemeyer	   and	   Jaenisch,	   2016).	   Second,	   in	   contrast	   to	   the	  
complex	  environment	  encountered	  in	  the	  brain,	  the	  reduced	  complexity	  of	  a	  cell	  culture	  model	  system	  
enables	  the	  effects	  of	  compounds	  on	  neuronal	  function	  to	  be	  directly	  tested.	  The	  accessibility	  of	  cells	  
in	  vitro	   also	   facilitates	   time-­‐lapse	   imaging	  studies	  as	  well	  as	  physiological	  and	  optogenetic	   studies.	  
Finally,	   hPSCs	   provide	   a	   theoretically	   limitless	   supply	   of	   hypothalamic	   neurons,	   which	   can	   be	  
differentiated	  	  on	  a	  large	  scale.	  The	  generation	  of	  large	  cell	  numbers	  enables	  proteomic	  studies	  and	  
facilitates	  the	  development	  of	  functional	  screens	  based	  on	  neuronal	  activity.	  	  
The	  protocols	  described	  below	  seek	  to	  complement	  and	  extend	  a	  recently	  published	  protocol	  
for	  human	  hypothalamic	  differentiation	  (Wang	  et	  al.,	  2016)	  in	  a	  number	  of	  ways.	  First,	  we	  provide	  an	  
updated	  version	  of	  our	  previously	  published	  protocol	  (Merkle	  et	  al.,	  2015)	  that	  utilises	  a	  chemically	  
defined	  medium	  for	  greater	  reproducibility,	  while	  enabling	  the	  production	  of	  a	  broader	  spectrum	  of	  
hypothalamic	  neurons	  than	  reported	  elsewhere,	  including	  POMC	  and	  AGRP	  neurons,	  as	  well	  as	  the	  
disease-­‐relevant	  HCRT,	  CRH	  and	  TRH	  neuron	  populations.	  Second,	  we	  provide	  protocols	  for	  cortical	  
neuron	  differentiations	  to	  enable	  direct	  comparison	  of	  hypothalamic	  differentiation	  quality,	  as	  well	  as	  
additional	  control	  measures	  to	  enable	  novice	  groups	  to	  confirm	  the	  success	  of	  their	  differentiation	  
without	  the	  need	  for	  specialised	  reagents	  such	  as	  NKX2.1	  reporter	  cell	  lines	  (Goulburn	  et	  al.,	  2011).	  
Third,	   we	   provide	   protocols	   for	   the	   maturation,	   long-­‐term	   culture,	   and	   functional	   studies	   of	  
hypothalamic	  neurons	  using	  calcium	  imaging.	  We	  hope	  that	  these	  protocols	  will	  enable	  more	  groups	  
to	  study	  the	  basic	  biology	  of	  hypothalamic	  neurons	  and	  develop	  new	  disease	  models	  to	  facilitate	  the	  
development	  of	  treatments	  for	  a	  range	  of	  human	  diseases.	  	  
	  
BASIC	  PROTOCOL	  1	  :	  HPSC	  MAINTENANCE	  (Figure	  1)	  
HESCs	  and	  hiPSCs	  should	  be	  maintained	  in	  conditions	  that	  stably	  promote	  pluripotency.	  hPSCs	  
are	  prone	  to	  spontaneous	  differentiation	  and	  genetic	  instability	  if	  not	  handled	  appropriately	  (Ronen	  
and	  Benvenisty,	  2012).	  The	  presence	  of	  spontaneously	  differentiated	  cells	  in	  hPSC	  cultures	  is	  likely	  to	  
interfere	  with	  efficient	  hypothalamic	  differentiation,	  and	  the	  presence	  of	  unwanted	  mutations	  will	  
complicate	   downstream	   analyses.	   Detailed	   methods	   for	   hPSC	   culture	   are	   provided	   elsewhere	  
(Andrews	  et	  al.,	  2010;	  Ludwig	  and	  A.	  Thomson,	  2007;	  Santos	  et	  al.,	  2016)	  
Briefly,	   hPSCs	   are	   maintained	   in	   the	   absence	   of	   antibiotics	   under	   feeder-­‐free	   conditions,	  
monitored	  and	  fed	  daily	  with	  complete	  media	  changes,	  and	  passaged	  using	  EDTA	  before	  they	  reach	  
confluence.	  Cell	   lines	  should	  be	  adapted	  to	  feeder-­‐free	  conditions	  and	  purified	  from	  differentiated	  
cells	  for	  at	  least	  two	  passages	  prior	  to	  seeding	  cells	  for	  differentiation.	  Cell	  lines	  should	  be	  routinely	  
monitored	   for	   pathogens	   such	   as	  mycoplasma,	   as	   well	   as	   the	   acquisition	   in	   culture	   of	   unwanted	  
mutations	  (Merkle	  et	  al.,	  2017;	  Amps	  et	  al.,	  2011;	  Baker	  et	  al.,	  2016).	  Also	  note	  that	  work	  with	  hESCs	  
is	  restricted	  in	  some	  countries	  and	  institutions,	  but	  can	  be	  replaced	  by	  hiPSCs	  for	  most	  applications.	  	  	  
	  
Materials	  
-­‐	  Geltrex	  LDEV-­‐Free	  Reduced	  Growth	  Factor	  Basement	  Membrane	  Matrix	  [Thermo	  Fisher	  Scientific,	  
cat.	  no.	  A1413202];	  
-­‐	  DMEM/F12	  without	  phenol	  red	  [Thermo	  Fisher	  Scientific,	  cat.	  no.	  21041025];	  
-­‐	  hiPSC	  or	  hESC	  cell	  line	  confirmed	  to	  be	  free	  of	  pathogens	  and	  unwanted	  mutations	  (e.g.	  WA09	  cell	  
line,	  WiCell,	  RRID:CVCL_9773)	  	  
-­‐	  Phosphate	  Buffered	  Saline,	  calcium	  and	  magnesium-­‐free	  (DPBS),	  pH	  range	  7.0-­‐7.3	  [Thermo	  Fisher	  
Scientific,	  cat.	  no.	  14190250];	  	  
-­‐	  Ethylenediaminetetraacetic	  acid	  (EDTA)	  [Sigma	  Aldrich,	  cat.	  no.	  03690]	  [see	  Reagents	  and	  Solutions];	  
-­‐	  mTeSR1	  medium	  [STEMCELL	  Technologies,	  see	  Reagents	  and	  Solutions];	  
-­‐	  Y-­‐27632	  dihydrochloride	  (Rock	  inhibitor)	  [DNSK	  International,	  cat.	  no.	  DNSK-­‐KI-­‐15-­‐02]	  [see	  Reagents	  
and	  Solutions];	  
-­‐	  DNase	  (vial	  D2)	  [Worthington	  Biochemical,	  cat.	  no.	  LK003172];	  
-­‐	  Parafilm	  [Sigma	  Aldrich,	  cat.	  no.	  P7793]	  
	  
*	  Equipment:	  
-­‐	  6-­‐well	  plate,	  12-­‐well	  plate,	  24-­‐well	  plate,	  or	  10	  cm	  plate;	  
-­‐	  15	  ml	  and	  50	  ml	  V-­‐bottom	  polypropylene	  tubes	  (e.g.	  Falcon	  tubes);	  
-­‐	  37°C,	  20%	  O2,	  5%	  CO2	  humidified	  incubator;	  
-­‐	  Laboratory	  centrifuge	  [Eppendorf	  Centrifuge	  5804,	  rotor	  A-­‐4-­‐44	  or	  similar];	  
-­‐	  Class	  II	  biosafety	  cabinet;	  
-­‐	  Inverted	  phase	  contrast	  microscope;	  
-­‐	  Vacuum	  aspiration	  system;	  
-­‐	  Pipettes:	  2-­‐10	  µl,	  20-­‐200	  µl,	  100-­‐1000	  µl	  and	  corresponding	  tips;	  
-­‐	  Automated	  pipetman	  and	  serological	  pipettes	  (5	  ml,	  10	  ml,	  25	  ml).	  
	  
	  
Protocol	  steps	  –	  Step	  annotation	  
To	  ensure	  cultures	  are	  kept	  sterile,	  cells	  should	  be	  handled	  in	  a	  Class	  II	  biosafety	  cabinet	  using	  standard	  
sterile	  technique	  at	  all	  times	  (Mather	  and	  Roberts,	  1998).	  
A-­‐   Coat	  6-­‐well	  plates	  or	  10	  cm	  plates	  with	  thin	  gel	  layer	  of	  Geltrex,	  a	  soluble	  reduced	  growth	  
factor	  basement	  membrane	  extract	  that	  facilitates	  cell	  attachment.	  	  	  	  
1-­‐   Thaw	  Geltrex	  matrix	  on	  ice	  overnight	  at	  4°C.	  
*	  Note	  -­‐	  Rapid	  Geltrex	  thawing	  can	  cause	  pre-­‐mature	  gelling,	  resulting	  in	  uneven	  coating.	  	  
2-­‐   Prepare	  a	  0.1%	  (1:10)	  Geltrex	  stock	  by	  diluting	  a	  5	  ml	  Geltrex	  vial	  in	  45	  ml	  ice-­‐cold	  DMEM/F12	  
without	  phenol	  red,	  gently	  pipette	  up	  and	  down	  to	  mix.	  During	  preparation,	  keep	  all	  reagents	  
on	  ice.	  Avoid	  freeze-­‐thaw	  cycles.	  
3-­‐   To	   prepare	   a	   working	   solution	   of	   Geltrex	   for	   hPSC	  maintenance,	   further	   dilute	   the	   stock	  
solution	  1:10	  in	  ice	  cold	  DMEM/F12	  without	  phenol	  red	  to	  a	  0.01%	  final	  concentration.	  Again,	  
keep	  all	  reagents	  on	  ice	  during	  this	  process.	  
4-­‐   Add	  1	  ml	  of	  cold	  0.01%	  Geltrex	  per	  well	  of	  a	  6-­‐well	  plate,	  or	  5	  ml	  per	  10	  cm	  plate,	  taking	  care	  
to	  avoid	  bubbles.	  	  
5-­‐   To	  coat	  plates	  for	  same-­‐day-­‐use,	  add	  Geltrex	  solution	  to	  the	  wells	  and	  incubate	  plate	  at	  37°C	  
for	  2	  hours.	  To	  coat	  plates	  for	  next-­‐day-­‐use,	  add	  Geltrex	  solution	  to	  the	  wells,	  wrap	  plates	  in	  
Parafilm	  and	  store	  them	  at	  4°C	  up	  to	  72h.	  Before	  use,	  incubate	  plate	  with	  Geltrex	  at	  37°C	  for	  
2	  hours.	  	  
6-­‐   Before	  plating	  cells,	  aspirate	  excess	  Geltrex	  and	  immediately	  gently	  rinse	  the	  plate	  one	  time	  
with	  an	  equal	  volume	  of	  PBS.	  The	  coated	  plate	  is	  ready	  to	  receive	  cells	  for	  plating	  as	  described	  
in	  step	  C,	  point	  8.	  	  
*After	  coating	  the	  plate,	  take	  care	  not	  to	  let	  it	  dry	  out	  at	  any	  time.	  Avoid	  bubbles.	  
	  
B-­‐   Feed	  cells	  daily	  with	  mTeSR1	  medium	  by	  aspirating	  old	  medium	  and	  providing	  a	  complete	  
media	   change.	   Note	   the	   morphology	   of	   the	   cultures	   (Figure	   1H).	   Colonies	   should	   be	  
uniform	   in	   appearance.	   Cells	   should	  have	   a	   high	  nuclear:cytoplasmic	   ratio	   (Figure	   1C),	  
contain	  prominent	  nucleoli,	  grow	  in	  colonies	  with	  well-­‐defined	  borders,	  and	  maintain	  cell-­‐
cell	  contact	  with	  other	  hSPCs.	  
*	  Note	  -­‐	  Skipping	  feedings	  can	  stress	  cells	  and	  adversely	  affect	  differentiation	  potential.	  Do	  
not	   attempt	   hypothalamic	   differentiation	   if	   there	   is	   evidence	   of	   cells	   with	   a	   morphology	  
different	  from	  that	  of	  hPSCs.	  Eliminate	  unwanted	  differentiated	  cells	  by	  aspirating	  them	  at	  
each	  feeding	  or	  by	  manually	  picking	  hPSC	  colonies	  as	  described	  elsewhere	  (Andrews	  et	  al.,	  
2010;	  Ludwig	  and	  A.	  Thomson,	  2007;	  Santos	  et	  al.,	  2016).	  	  
	  
C-­‐   When	  hPSCs	  reach	  80-­‐90%	  confluence	  (Figure	  1A)	  (approximately	  3-­‐4	  days	  after	  previous	  
split),	  split	  cells	  1:6	  	  
	  
1-­‐   Preheat	  desired	  volume	  of	  EDTA	  solution	  in	  a	  37°C	  water	  bath	  for	  approximately	  10	  minutes.	  
2-­‐   Wash	  cells	  gently	  and	  briefly	  with	  room-­‐temperature	  DPBS.	  
3-­‐   Add	  warm	  EDTA	  to	  cultures,	  1	  ml	  per	  well	  in	  6-­‐well	  plate,	  5	  ml	  per	  10	  cm	  plate.	  
4-­‐   Incubate	  with	  EDTA	  for	  3-­‐5	  minutes	  at	  37°C.	  After	  3	  minutes,	  check	  for	  cell	  detachment	  on	  a	  
phase	  contrast	  microscope.	  Cells	  should	  start	  to	  round	  up	  and	  take	  a	  phase-­‐bright	  appearance	  
(Figure	  1D	  and	  1E),	  but	  not	  spontaneously	  detach	  from	  the	  plate.	  Once	  cultures	  adopt	  this	  
appearance,	   gently	   suck	   up	   and	  dispel	   ~100	  µl	   of	   the	   EDTA	   solution	  with	   a	   P1000	  pipette	  
against	  the	  cells.	  They	  should	  easily	  dislodge	  and	  leave	  a	  small	  area	  devoid	  of	  cells.	  If	  cells	  do	  
not	  dissociate	  easily,	  extend	  EDTA	  digestion	  for	  another	  minute	  and	  repeat	  this	  test.	  	  
5-­‐   Once	  cells	  can	  easily	  be	  detached	  from	  the	  plate,	  but	  before	  they	  spontaneously	  lift	  off,	  gently	  
aspirate	  EDTA.	  
6-­‐   To	  dissociate	  cells,	  add	  1	  ml	  or	  5	  ml	  mTeSR1	  +	  Y-­‐27632	  for	  a	  well	  of	  a	  6	  well	  plate	  or	  10	  cm	  
plate,	  respectively.	  Gently	  pipette	  this	  medium	  over	  the	  plate	  to	  detach	  cells	  and	  pipette	  up	  
and	  down	  several	  times	  dissociate	  them	  to	  suspension	  of	  small	  clumps	  of	  cells.	  Avoid	  bubbles.	  
7-­‐   Collect	  cells	  in	  15	  ml	  V-­‐bottom	  polypropylene	  tube,	  and	  adjust	  volume	  with	  mTeSR1	  +	  Y-­‐27632	  
if	  necessary.	  
8-­‐   Plate	   the	   desired	   volume	   of	   this	   cell	   suspension	   to	   achieve	   a	   1:4	   to	   1:10	   split	   ratio	   onto	  
Geltrex-­‐coated	  plates	  (see	  above)	  in	  mTeSR1	  +	  Y-­‐27632,	  bringing	  the	  final	  volume	  to	  2	  ml	  per	  
well	  of	  a	  6	  well	  plate	  or	  10	  ml	  per	  10	  cm	  plate.	  Culture	  cells	  in	  mTeSR1	  +	  Y-­‐27632	  for	  one	  day	  
at	   37°C,	  20%	  O2,	   5%	   CO2	   humidified	   incubator,	   then	  maintain	   them	   by	   feeding	   daily	  with	  
mTeSR1	  medium.	  	  
*	  Note	  -­‐	  The	  split	  ratio	  will	  vary	  somewhat	  depending	  on	  the	  growth	  properties	  of	  the	  cell	  
lines.	  Cultures	  should	  be	  passaged	  approximately	  every	  4	  days.	  	  
9-­‐   Depending	   on	   experimental	   design,	   expand	   culture	   to	   provide	   sufficient	   cell	   numbers	   for	  
differentiation.	  A	  90%	  confluent	  plate	  10	  cm	  or	  15	  cm	  plate	  of	  hPSC	  yields	  about	  8	  x	  106	  or	  2	  
x	  107	  cells,	  respectively.	  	  
	  
BASIC	  PROTOCOL	  2:	  HYPOTHALAMIC	  DIFFERENTIATION	  (Figure	  2)	  
The	   efficient	   generation	   of	   human	   hypothalamic	   neurons	   from	   hPSCs	   is	   based	   on	  
developmental	  principles.	  The	  signalling	  pathways	  that	  lead	  to	  neuralization,	  forebrain	  specification,	  
and	   ventralization	   are	   manipulated	   by	   small	   molecule	   drugs.	   Specifically,	   the	   Wingless-­‐related	  
integration	   site	   (WNT),	   transforming	   growth	   factor	   beta	   (TGFβ)	   and	   bone	  morphogenetic	   protein	  
(BMP)	   signalling	   pathways	   are	   inhibited	   with	   XAV939,	   LDN-­‐193189	   and	   SB431542,	   respectively,	  
followed	  by	  activation	  of	   the	  Sonic	  Hedgehog	   (SHH)	  pathway	  with	  Purmorphamine	  and	  Smoothed	  
agonist	   (SAG).	   Later	   addition	   of	   the	   gamma-­‐secretase	   inhibitor	   DAPT	   promotes	   neurogenesis	   by	  
inhibiting	  NOTCH	  signalling	  [Figure	  2A]	  (Merkle	  et	  al.,	  2015;	  Wang	  et	  al.,	  2015).	  	  
This	  protocol	  is	  designed	  for	  adherent	  differentiation	  in	  monolayers.	  Typically,	  more	  than	  1	  x	  
108	  neurons	  are	  generated	  per	  10	  cm	  plate	  of	  hPSCs,	  providing	  large	  numbers	  of	  human	  hypothalamic	  
neurons	   for	   functional	   studies,	   disease	   modelling,	   cellular	   transplantation,	   or	   drug	   screening.	   In	  
contrast	   to	   previously	   published	   studies	   (Merkle	   et	   al.,	   2015;	   Wang	   et	   al.,	   2016),	   the	   protocol	  
described	  below	  omits	  animal-­‐derived	  products	  such	  as	  knockout-­‐serum	  replacement	  (KOSR)	  medium	  
and	  recombinant	  proteins	  in	  favour	  of	  chemically	  defined	  media	  and	  small	  molecule	  drugs	  to	  ensure	  
greater	   robustness	   and	   reproducibility.	   Furthermore,	   the	   resulting	   cells	   can	   be	   matured	   and	  
maintained	   over	   long	   periods	   of	   time	   (at	   least	   6	   months)	   to	   enable	   the	   study	   of	   long-­‐term	  
developmental	  processes.	  	  
	  
Materials	  
-­‐	  Geltrex	  LDEV-­‐Free	  Reduced	  Growth	  Factor	  Basement	  Membrane	  Matrix	  [Thermo	  Fisher	  Scientific,	  
cat.	  no.	  A1413202];	  
-­‐	  Nearly	  confluent	  culture	  of	  hESCs	  or	  hiPSCs	  (generated	  in	  BASIC	  PROTOCOL	  1)	  
-­‐	  Phosphate	  Buffered	  Saline,	  calcium	  and	  magnesium-­‐free	  (DPBS),	  pH	  range	  7.0-­‐7.3	  [Thermo	  Fisher	  
Scientific,	  cat.	  no.	  14190250];	  
-­‐	  TrypLE	  Express	  1X,	  no	  phenol	  red	  [Life	  Technologies,	  cat.	  no.	  12604021];	  
-­‐	  mTeSR1	  medium	  [see	  Reagents	  and	  Solutions];	  
-­‐	  hPSC	  wash	  medium	  [see	  Reagents	  and	  Solutions];	  
-­‐	  Trypan	  blue	  [Invitrogen,	  cat.	  no.	  T10282];	  
-­‐	  Y-­‐27632	  dihydrochloride	  Rock	  inhibitor	  [DNSK	  International,	  cat.	  no.	  DNSK-­‐KI-­‐15-­‐02]	  [see	  Reagents	  
and	  Solutions];	  
-­‐	  N2B27	  medium	  [see	  Reagents	  and	  Solutions];	  
-­‐	  Dimethyl	  Sulfoxide,	  DMSO	  [Sigma	  Aldrich,	  cat.	  no.	  D2650-­‐100ml];	  
-­‐	  Bovine	  Serum	  Albumin,	  BSA	  [Sigma	  Aldrich,	  cat.	  no.	  A0281];	  
-­‐	  XAV939	  [Stemgent,	  cat.	  no.	  04-­‐0046]	  [see	  Reagents	  and	  Solutions];	  
-­‐	  LDN-­‐193189	  [Stemgent,	  cat.	  no.	  04-­‐0074]	  [see	  Reagents	  and	  Solutions];	  
-­‐	  SB431542	  [Sigma	  Aldrich,	  cat.	  no.	  S4317]	  [see	  Reagents	  and	  Solutions];	  
-­‐	   Smoothened	   agonist	   (SAG)	   [Fisher	   Scientific	   (EMD	   Millipore)	   cat.	   no.	   56-­‐666-­‐01MG,	   or	   DNSK	  
International	  custom	  order,	  DNSK-­‐SMO-­‐1]	  [see	  Reagents	  and	  Solutions];	  
-­‐	  Purmorphamine	  [Calbiochem	  (EMD	  Millipore)	  cat.	  no.	  540220,	  or	  DNSK	  International	  custom	  order]	  
[see	  Reagents	  and	  Solutions];	  
-­‐	   DAPT	   [Sigma	   Aldrich,	   cat.	   no.	   D5942,	   or	   DNSK	   International	   custom	   order]	   [see	   Reagents	   and	  
Solutions];	  
-­‐	  Brain-­‐derived	  neurotrophic	  factor	  (BDNF)	  [Pepro	  Tech,	  cat.	  no.	  450-­‐02]	  [see	  Reagents	  and	  Solutions];	  
-­‐	  Maturation	  medium	  [see	  Reagents	  and	  Solutions];	  
	  
*	  Equipment:	  
-­‐	  6-­‐well	  plate,	  12-­‐well	  plate,	  24-­‐well	  plate,	  or	  10	  cm	  plate;	  
-­‐	  15	  ml	  and	  50	  ml	  V-­‐bottom	  polypropylene	  tube	  (e.g.	  Falcon	  tubes);	  
-­‐	  Automated	  cell	  counter	  and	  associated	  consumables	  [e.g.	  Life	  Technologies,	  Countess	  II	  Automated	  
Cell	  Counter,	  cat	  no.	  AMQAX1000];	  
-­‐	  Cell	  counting	  slide	  [Countess	  Cell	  Counting	  Chamber	  Slides,	  cat.	  no.	  C10228];	  
-­‐	  37°C,	  5%	  CO2	  humidified	  incubator;	  
-­‐	  Laboratory	  centrifuge	  [Eppendorf	  Centrifuge	  5804,	  rotor	  A-­‐4-­‐44	  or	  similar];	  
-­‐	  Class	  II	  biosafety	  cabinet;	  
-­‐	  Inverted	  phase	  contrast	  microscope;	  
-­‐	  Vacuum	  aspiration	  system;	  
-­‐	  Pipettes:	  2-­‐10	  µl,	  20-­‐200	  µl,	  100-­‐1000	  µl	  and	  corresponding	  tips;	  
-­‐	  Automated	  pipetman	  and	  serological	  pipettes	  (5	  ml,	  10	  ml,	  25	  ml);	  
-­‐	  0.5	  or	  1.5	  ml	  polypropylene	  tubes	  [e.g.	  Eppendorf	  tubes].	  
	  
Protocol	  steps	  	  
A-­‐   Coat	   6-­‐well	   plates	   or	   10	   cm	  plates	  with	  Geltrex	   for	   differentiation	   as	   described	   above	  
(BASIC	  PROTOCOL	  1,	  A).	  
B-­‐   hPSCs	  (cultured	  in	  BASIC	  PROTOCOL	  1)	  are	  dissociated	  and	  re-­‐plated	  for	  differentiation.	  
*	  Note	  -­‐	  Before	  induction	  of	  differentiation,	  hPSCs	  should	  lack	  obvious	  signs	  of	  differentiation	  
or	  contamination,	  and	  be	  in	  a	  rapid	  growth	  phase.	  	  
1-­‐   Aspirate	  culture	  medium	  and	  briefly	  and	  gently	  wash	  cell	  culture	  in	  room	  temperature	  PBS.	  
2-­‐   Add	  37°C	  TrypLE	  to	  cell	  culture,	  1	  ml	  per	  well	  in	  6-­‐well	  plate,	  5	  ml	  per	  10	  cm	  plate.	  
3-­‐   Incubate	  cell	  culture	  for	  3-­‐5	  minutes	  at	  37°C.	  After	  a	  3	  minute	  incubation,	  check	  to	  see	  if	  cells	  
are	  detaching.	  Under	  a	  phase	  contrast	  microscope,	  the	  cells	  should	  start	  to	  round	  up	  and	  take	  
on	  a	  phase-­‐bright	  appearance,	  but	  not	  spontaneously	  detach	  from	  the	  plate.	  Once	  cultures	  
adopt	  this	  appearance,	  gently	  suck	  up	  and	  dispel	  ~100	  µl	  of	  the	  TrypLE	  solution	  with	  a	  P1000	  
pipette	  against	  the	  cells.	  They	  should	  easily	  dislodge	  and	  leave	  a	  small	  area	  devoid	  of	  cells.	  If	  
cells	  do	  not	  dissociate	  easily,	  extend	  TrypLE	  digestion	  for	  another	  minute	  and	  repeat	  this	  test.	  	  
*	  Note	  -­‐	  Take	  care	  to	  avoid	  over-­‐digestion,	  which	  can	  cause	  cell	  death.	  	  
4-­‐   Gently	  aspirate	  TrypLE.	  
5-­‐   To	  dissociate	  cells,	  add	  1	  ml	  or	  5	  ml	  mTeSR1	  +	  Y-­‐27632	  for	  a	  well	  of	  a	  6	  well	  plate	  or	  10	  cm	  
plate,	   respectively,	   and	   gently	   pipette	   this	   medium	   over	   the	   plate	   to	   detach	   cells	   and	  
dissociate	  them	  to	  a	  single-­‐cell	  suspension.	  	  
6-­‐   Collect	  cells	  in	  15	  ml	  V-­‐bottom	  polypropylene	  tube,	  and	  adjust	  volume	  with	  mTeSR1	  +	  Y-­‐27632	  
(total	  volume	  =	  10	  ml).	  This	  wash	  steps	  dilutes	  residual	  TrypLE	  to	  slow	  further	  digestion.	  
7-­‐   Centrifuge	  cells	  at	  160	  x	  g	   for	  3-­‐5	  minutes	  at	   room	  temperature.	  Aspirate	  supernatant,	   re-­‐
suspend	  cells	  in	  1	  ml	  hPSC	  wash	  medium	  with	  a	  P1000,	  then	  bring	  to	  10	  ml	  with	  wash	  medium.	  	  
8-­‐   Centrifuge	  cells	  at	  160	  x	  g	   for	  3-­‐5	  minutes	  at	   room	  temperature.	  Aspirate	  supernatant,	   re-­‐
suspend	  cells	  in	  1	  ml	  mTeSR1	  +	  Y-­‐27632.	  These	  wash	  steps	  remove	  any	  remaining	  traces	  of	  
TrypLE.	  
9-­‐   After	  re-­‐suspending	  the	  cell	  pellet,	  adjust	  volume	  so	  that	  the	  suspension	  is	  visibly	  turbid,	  but	  
not	  milky	  (approximately	  1-­‐5	  x	  106	  cells/ml).	  
10-­‐  In	  a	  0.5	  ml	  polypropylene	  tube,	  mix	  10	  µl	  of	  this	  cell	  suspension	  with	  10	  µl	  Trypan	  blue,	  transfer	  
10	  µl	  of	  that	  mixture	  onto	  cell	  counting	  slide.	  Count	  cells	  with	  automated	  cell	  counter.	  
11-­‐  Plate	  cells	  onto	  Geltrex-­‐coated	  plates	  in	  mTeSR1	  +	  Y-­‐27632,	  at	  a	  concentration	  of	  1	  x	  105	  cells	  
per	  cm2	  (corresponding	  to	  9.5	  x	  105	  cells	  per	  well	  of	  a	  6-­‐well	  plate,	  or	  5.5	  x	  106	  cells	  per	  10	  cm	  
plate).	  This	  density	  corresponds	  to	  approximately	  80%	  confluence	  the	  following	  day.	  Ensure	  
that	  cells	  are	  evenly	  distributed	  across	  the	  plate	  by	  gently	  shaking	  the	  plate	  left	  to	  right,	  then	  
top	  to	  bottom	  after	  transferring	  it	  to	  the	  incubator.	  
*	   Note	   -­‐	   If	   cells	   are	   sparser,	   wait	   until	   cells	   reach	   the	   desired	   density	   before	   starting	   the	  
differentiation.	  Sparse	  or	  over-­‐confluent	  cells	  will	  not	  pattern	  well.	  	  
12-­‐  If	   cells	   plated	   for	   differentiation	   are	   evenly	   distributed	   over	   the	   plate	   and	   at	   a	   density	   of	  
approximately	  75%	  (Figure	  2B	  and	  2B'),	  start	  differentiation	  by	  washing	  cultures	  once	  with	  
PBS	  and	  adding	  Day	  0	  (D0)	  medium	  (see	  below).	  Every	  second	  day,	  make	  full	  medium	  changes	  
as	  follows	  (5-­‐6	  ml	  per	  6-­‐well	  plate,	  10-­‐15	  ml	  per	  10	  cm	  plate):	  
•   Day	  0	  (D0):	  N2B27	  +	  2	  µM	  XAV939	  +	  100	  nM	  LDN-­‐193189	  +	  10	  µM	  SB431542	  
•   Day	  2	  (D2):	  N2B27	  +	  2	  µM	  XAV939	  +	  100	  nM	  LDN-­‐193189	  +	  10	  µM	  SB431542	  +	  1	  µM	  
SAG	  +	  1	  µM	  Purmorphamine	  
•   Day	  4	  (D4):	  N2B27	  +	  1.5	  µM	  XAV939	  +	  75	  nM	  LDN-­‐193189	  +	  7.5	  µM	  SB431542	  +	  1	  µM	  
SAG	  +	  1	  µM	  Purmorphamine	  
•   Day	  6	  (D6):	  N2B27	  +	  1	  µM	  XAV939	  +	  50	  nM	  LDN-­‐193189	  +	  5	  µM	  SB431542	  +	  1	  µM	  SAG	  
+	  1	  µM	  Purmorphamine	  
•   Day	  8	  (D8):	  N2B27	  +	  0.5	  µM	  XAV939	  +	  25	  nM	  LDN-­‐193189	  +	  2.5	  µM	  SB431542	  +	  5	  µM	  
DAPT	  
•   Day	  10	  (D10):	  N2B27	  +	  5	  µM	  DAPT	  
•   Day	  12	  (D12):	  N2B27	  +	  5	  µM	  DAPT	  
•   Day	  14	   (D14):	  dissociation	  and	  re-­‐plating	   in	  Maturation	  medium	  +	  5	  µM	  DAPT	  +	  Y-­‐
27632	  (see	  Basic	  Protocol	  3)	  
	  
13-­‐  Observe	   cells	   daily	   for	   changes	   in	   morphology.	   From	   Days	   0-­‐2,	   the	   culture	   should	   reach	  
confluence	  and	  cells	  should	  have	  a	  simple	  and	  uniform	  hPSC-­‐like	  morphology	  (Figure	  2C	  and	  
2C').	  By	  Day	  4,	  cultures	  are	  highly	  compacted	  and	  cells	  adopt	  a	  more	  rounded	  appearance	  
(Figure	   2D	   and	   2D').	   Between	  Days	   4	   and	   8,	   the	   cultures	   take	   on	   a	   dense	   neuroepithelial	  
morphology	   with	   identifiable	   neural	   ridge-­‐like	   structures.	   (Figure	   2E	   and	   2E').	   A	  
neuroepithelial	  morphology	  is	  still	  evident	  before	  passaging	  on	  Day	  14	  (Figure	  2F	  and	  F').	  For	  
issues	   that	   can	   arise	   during	   the	   differentiation	   process,	   please	   see	   the	   Troubleshooting	  
section.	  
	  
SUPPORT	  PROTOCOL	  1:	  CORTICAL	  NEURON	  (CONTROL)	  DIFFERENTIATION	  
In	  order	   to	   confirm	  correct	   and	  efficient	  hypothalamic	  patterning	  of	  hPSCs,	   it	   is	  helpful	   to	  
compare	  hypothalamic	  differentiation	  to	  a	  parallel	  differentiation	  of	  hPSCs	  to	  cortical	  neurons	  (Shi	  et	  
al.,	  2012).	  To	  facilitate	  parallel	  culture,	  the	  time	  course	  and	  basic	  procedure	  of	  this	  differentiation	  is	  
similar	  to	  hypothalamic	  differentiation,	  except	  that	  ventralizing	  factors	  (SAG	  and	  Purmorphamine)	  are	  
omitted	  and	  DAPT	  is	  replaced	  with	  FGF2.	  	  
	  
Materials	  
-­‐	  Follow	  the	  list	  of	  Materials	  from	  BASIC	  PROTOCOL	  2;	  
-­‐	  FGF2	  [Sigma	  Aldrich,	  cat.no.	  F0291]	  [see	  Reagents	  and	  Solutions].	  
	  
Protocol	  steps	  –	  Step	  annotation	  
Follow	  the	  steps	  from	  1	  to	  10	  from	  BASIC	  PROTOCOL	  2.	  
11-­‐  If	   cells	   plated	   for	   differentiation	   are	   evenly	   distributed	   over	   the	   plate	   and	   at	   a	   density	   of	  
approximately	  75%,	  start	  the	  differentiation	  by	  washing	  cultures	  once	  with	  DPBS	  and	  adding	  
Day	  0	  (D0)	  medium	  (see	  below).	  Every	  second	  day,	  make	  full	  media	  changes	  as	  follows:	  
•   Day	  0	  (D0):	  N2B27	  +	  2	  µM	  XAV939	  +	  100	  nM	  LDN-­‐193189	  +	  10	  µM	  SB431542	  
•   Day	  2	  (D2):	  N2B27	  +	  2	  µM	  XAV939	  +	  100	  nM	  LDN-­‐193189	  +	  10	  µM	  SB431542	  	  
•   Day	  4	  (D4):	  N2B27	  +	  1.5	  µM	  XAV939	  +	  75	  nM	  LDN-­‐193189	  +	  7.5	  µM	  SB431542	  	  
•   Day	  6	  (D6):	  N2B27	  +	  1	  µM	  XAV939	  +	  50	  nM	  LDN-­‐193189	  +	  5	  µM	  SB431542	  	  
•   Day	  8	  (D8):	  N2B27	  +	  0.5	  µM	  XAV939	  +	  25	  nM	  LDN-­‐193189	  +	  2.5	  µM	  SB431542	  
•   Day	  10	  (D10):	  N2B27	  	  
•   Day	  12	  (D12):	  N2B27	  +	  20	  ng/ml	  FGF2	  
•   Day	  14	  (D14):	  dissociation	  and	  re-­‐plating	  in	  Maturation	  medium	  +	  20	  ng/ml	  FGF2	  +	  Y-­‐	  
Y-­‐27632	  (see	  Basic	  Protocol	  3)	  
	  
BASIC	  PROTOCOL	  3	  :	  NEURONAL	  MATURATION	  
The	  aim	  of	  this	  protocol	  is	  to	  create	  mature	  hypothalamic	  neurons	  that	  are	  spontaneously	  electrically	  
active	  and	  that	  respond	  to	  exogenous	  factors,	  such	  as	  leptin.	  To	  promote	  maturation	  and	  induction	  of	  
target	  genes	  such	  as	  POMC,	  cultures	  are	  re-­‐plated	  at	  1	  x	  105	  cells	  per	  cm2	  and	  10	  ng/ml	  brain-­‐derived	  
neurotrophic	  factor	  (BDNF)	  is	  added	  to	  the	  culture	  medium.	  In	  our	  hands,	  hypothalamic	  neurons	  begin	  
to	  acquire	  functional	  properties	  after	  30	  days	  of	  culture	  in	  the	  absence	  of	  exogenously	  added	  primary	  
glia,	  and	  mature	  further	  over	  subsequent	  weeks	  in	  culture.	  Plating	  dissociated	  human	  neurons	  on	  a	  
monolayer	   of	   glia	   (3	   x	   104	   cells	   per	   cm2)	   harvested	   from	   the	   newborn	   mouse	   or	   rat	   brain	   may	  
accelerate	  functional	  maturation	  and	  may	  be	  particularly	  valuable	  for	  experiments	  in	  which	  neurons	  
are	  plated	  at	  low	  densities	  or	  are	  to	  be	  used	  for	  electrophysiological	  recording	  (Zuchero	  and	  Barres,	  
2015;	  Ullian	  et	  al.,	  2001).	  Protocols	  for	  glial	  isolation	  and	  culture	  are	  described	  elsewhere	  (Foo	  et	  al.,	  
2011;	  Albuquerque	  et	  al.,	  2009).	  The	  same	  maturation	  protocol	  can	  be	  used	  for	  hypothalamic	  and	  
cortical	  differentiation.	  
Materials	  
-­‐	  Geltrex	  LDEV-­‐Free	  Reduced	  Growth	  Factor	  Basement	  Membrane	  Matrix	  [Thermo	  Fisher	  Scientific,	  
cat.	  no.	  A1413202];	  
-­‐	  Neural	  progenitor	  cells	  after	  differentiation	  from	  BASIC	  PROTOCOL	  2;	  
-­‐	  Phosphate	  Buffered	  Saline,	  calcium	  and	  magnesium-­‐free	  (DPBS),	  pH	  range	  7.0-­‐7.3	  [Thermo	  Fisher	  
Scientific,	  cat.	  no.	  14190250];	  
-­‐	  TrypLE	  Express	  1X,	  no	  phenol	  red	  [Life	  Technologies,	  cat.	  no.	  12604021];	  
-­‐	  Trituration	  medium	  [see	  Reagents	  and	  Solutions];	  
-­‐	  Maturation	  medium	  [see	  Reagents	  and	  Solutions];	  
-­‐	  Y-­‐27632	  dihydrochloride	  (Rock	  inhibitor)	  [DNSK	  International,	  cat.	  no.	  DNSK-­‐KI-­‐15-­‐02]	  [see	  Reagents	  
and	  Solutions];	  
-­‐	  Trypan	  blue	  stain	  0.4%	  [Invitrogen,	  cat.	  no.	  AM7962];	  
-­‐	  Brain-­‐derived	  neurotrophic	  factor	  (BDNF)	  [Pepro	  Tech,	  cat.	  no.	  450-­‐02]	  [see	  Reagents	  and	  Solutions];	  
-­‐	  Papain	  [Thermo	  Fisher	  Scientific,	  cat	  no.	  88290]	  [see	  Reagents	  and	  Solutions];	  
-­‐	  Human	  brain	  reference	  total	  RNA	  [Thermo	  Fisher	  Scientific,	  cat.	  no.	  AM6050];	  
	  
*	  Equipment:	  	  
-­‐	  6-­‐well	  plate,	  12-­‐well	  plate,	  24-­‐well	  plate,	  or	  10	  cm	  plate;	  
-­‐	  15	  ml	  and	  50	  ml	  V-­‐bottom	  polypropylene	  tube	  (e.g.	  Falcon	  tubes);	  
-­‐	  Automated	  cell	  counter	  and	  associated	  consumables	  [e.g.	  Life	  Technologies,	  Countess	  II	  Automated	  
Cell	  Counter,	  cat	  no.	  AMQAX1000];	  
-­‐	  Cell	  counting	  slide	  [Countess	  Cell	  Counting	  Chamber	  Slides,	  cat.	  no.	  C10228];	  
-­‐	  37°C,	  5%	  CO2	  humidified	  incubator;	  
-­‐	  Laboratory	  centrifuge	  [Eppendorf	  centrifuge	  5804,	  rotor	  A-­‐4-­‐44	  or	  similar];	  
-­‐	  Class	  II	  biosafety	  cabinet;	  
-­‐	  Inverted	  phase	  contrast	  microscope;	  
-­‐	  Vacuum	  aspiration	  system;	  
-­‐	  Pipettes:	  2-­‐10	  µl,	  20-­‐200	  µl,	  100-­‐1000	  µl	  and	  corresponding	  tips;	  
-­‐	  Automated	  pipetman	  and	  serological	  pipettes	  (5	  ml,	  10	  ml,	  25	  ml);	  
	  
Protocol	  steps	  	  
A-­‐   Coat	  plates	  with	  Geltrex	  for	  differentiation	  as	  described	  above	  (BASIC	  PROTOCOL	  1,	  A),	  
except	  use	  a	  0.02%	  final	  Geltrex	  concentration	  to	  facilitate	  neuronal	  attachment	  and	  long-­‐
term	  culture.	  
B-­‐   On	  Day	  14,	  neural	  progenitors	  generated	  in	  BASIC	  PROTOCOL	  2	  or	  SUPPORT	  PROTOCOL	  1	  
are	   dissociated	   and	   re-­‐plated	   to	   encourage	   neurogenesis	   and	   neuronal	   survival	   and	  
maturation.	  	  
1-­‐   Wash	  cell	  culture	  gently	  in	  PBS.	  
2-­‐   Add	  TrypLE	  to	  cells,	  1	  ml	  per	  well	  in	  6	  well	  plate,	  5	  ml	  per	  10	  cm	  plate.	  
3-­‐   Incubate	  cell	  culture	  for	  3-­‐5	  minutes	  at	  37°C.	  After	  3	  minutes	  of	  incubation,	  check	  to	  see	  if	  
cells	  are	  detaching.	  Under	  a	  phase	  contrast	  microscope,	  the	  cells	  should	  start	  to	  round	  up	  and	  
take	   on	   a	   phase-­‐bright	   appearance,	   but	   not	   spontaneously	   detach	   from	   the	   plate.	   Once	  
cultures	  adopt	  this	  appearance,	  gently	  suck	  up	  and	  dispel	  ~100	  µl	  of	  the	  TrypLE	  solution	  with	  
a	  P1000	  pipette	  against	  the	  cells.	  They	  should	  easily	  dislodge	  and	  leave	  a	  small	  area	  devoid	  of	  
cells.	  If	  cells	  do	  not	  dissociate	  easily,	  extend	  TrypLE	  digestion	  for	  another	  minute	  and	  repeat	  
this	  test.	  	  
*	  Note	  -­‐	  Take	  care	  to	  avoid	  over-­‐digestion,	  which	  can	  cause	  cell	  death	  and	  release	  of	  genomic	  
DNA.	  	  
4-­‐   Gently	  aspirate	  TrypLE.	  
5-­‐   To	  dissociate	  cells,	  add	  1	  ml	  or	  5	  ml	  trituration	  medium	  for	  a	  well	  of	  a	  6	  well	  plate	  or	  10	  cm	  
plate,	   respectively,	   and	   gently	   pipette	   this	   medium	   over	   the	   plate	   to	   detach	   cells	   and	  
dissociate	  them	  to	  a	  single-­‐cell	  suspension.	  	  
6-­‐   Collect	   cells	   in	   15	   ml	   V-­‐bottom	   polypropylene	   tube,	   and	   adjust	   volume	   with	   trituration	  
medium	  (total	  volume	  =	  10	  ml).	  
7-­‐   Centrifuge	  cells	  at	  160	  x	  g	   for	  3-­‐5	  minutes	  at	   room	  temperature.	  Aspirate	  supernatant,	   re-­‐
suspend	  cells	  in	  10	  ml	  trituration	  medium.	  
8-­‐   After	  re-­‐suspending	  the	  cell	  pellet,	  adjust	  volume	  so	  that	  the	  suspension	  is	  visibly	  turbid,	  but	  
not	  milky	  (approximately	  1-­‐5	  million	  cells/ml).	  
9-­‐   In	  a	  0.5	  ml	  polypropylene	  tube,	  mix	  10	  µl	  of	  this	  cell	  suspension	  with	  10	  µl	  Trypan	  blue,	  transfer	  
10	  µl	  of	  that	  mixture	  onto	  cell	  counting	  slide.	  Count	  cells	  with	  automated	  cell	  counter.	  
10-­‐  Centrifuge	  cells	  at	  160	  x	  g	   for	  3-­‐5	  minutes	  at	   room	  temperature.	  Aspirate	  supernatant,	   re-­‐
suspend	  cells	  in	  a	  desired	  volume	  of	  maturation	  medium	  +	  Y-­‐27632	  to	  enable	  plating	  at	  the	  
desired	  density.	  
*	   Note	   -­‐	   If	   desired,	   cultures	   can	   be	   frozen	   at	   this	   point	   for	   later	   thawing	   as	  
progenitors/immature	  neurons	  using	  the	  same	  procedure	  used	  for	  freezing	  hPSCs	  (Santos	  et	  
al.,	  2016).	  	  
11-­‐  Plate	  cells	  onto	  Geltrex-­‐coated	  plates	  in	  maturation	  medium	  +	  Y-­‐27632	  at	  a	  concentration	  of	  
1	  x	  105	  cells	  per	  cm2	  (corresponding	  to	  9.5	  x	  105	  cells	  per	  well	  of	  a	  6	  well	  plate,	  or	  5.5	  x	  106	  
cells	  per	  10	  cm	  plate).	  
12-­‐  On	  Day	  15,	  aspirate	  medium	  and	  feed	  with	  maturation	  medium.	  
13-­‐  On	  Day	  16,	  aspirate	  medium	  and	  add	  twice	  the	  normal	  volume	  of	  maturation	  medium	  (e.g.	  4	  
ml	  per	  well	  of	  a	  6	  well	  plate,	  20	  ml	  per	  10	  cm	  plate)	  for	  neuronal	  maintenance.	  This	   larger	  
volume	  helps	  ensure	  that	  neurons	  are	  exposed	  to	  a	  relatively	  constant	  supply	  of	  nutrients.	  
14-­‐  Change	  75%	  of	  media	  volume	  every	  second	  day.	  BDNF	  should	  be	  added	  fresh	  at	  each	  feeding.	  	  
On	   Day	   30,	   repeat	   the	   dissociation	   procedure	   outlined	   in	   steps	   1-­‐11,	   with	   the	   following	  
exception:	  resuspend	  1	  vial	  of	  Papain	  to	  10	  ml	  of	  TrypLE	  at	  step	  2.	  Papain	  aids	   in	  neuronal	  
dissociation	  and	  will	  ensure	  significantly	  higher	  survival	  upon	  re-­‐plating.	  	  
*	  Note	  -­‐	  It	  may	  be	  desirable	  to	  perform	  re-­‐plating	  slightly	  earlier	  (such	  as	  Day	  25	  when	  genes	  
such	  as	  POMC	  become	  robustly	  expressed)	  or	  later	  (such	  as	  Day	  40	  when	  genes	  such	  as	  HCRT	  
become	  robustly	  expressed).	  	  
15-­‐  After	  replating	  neurons	  at	  a	  later	  time	  point	  such	  as	  Day	  30,	  aspirate	  medium	  and	  add	  twice	  
the	  normal	  volume	  of	  maturation	  medium	  (e.g.	  4	  ml	  per	  well	  of	  a	  6	  well	  plate,	  20	  ml	  per	  10	  
cm	  plate)	   for	   neuronal	  maintenance.	  Cell	   cultures	   can	  be	  maintained	   in	   this	  manner	   for	   6	  
months	  or	  more,	  although	  cell	  detachment	  can	  become	  an	  issue	  (see	  Troubleshooting).	  	  
*	  Note	  -­‐	  If	  long-­‐term	  culture	  is	  desired,	  consider	  culturing	  cells	  at	  lower	  density	  (2	  x	  104	  cell	  
per	  cm2)	  on	  a	  monolayer	  of	  primary	  astrocytes	  plated	  on	  Geltrex-­‐coated	  plastic.	  Also	  note	  that	  
non-­‐neuronal	  cells	  maycontinue	  to	  proliferate	  and	  can	  lead	  to	  culture	  overgrowth.	  Although	  
cultures	   can	   be	  maintained	   for	   long	   periods	   of	   time,	   many	   experiments	   can	   be	   executed	  
between	  Day	  30-­‐80.	  
	  
SUPPORT	  PROTOCOL	  2:	  QUALITY	  CONTROL	  –	  CONFIRMATION	  OF	  HYPOTHALAMIC	  PATTERNING	  AND	  
NEUROGENESIS	  
To	  confirm	  successful	  hypothalamic	  patterning	  and	  generation	  of	  hypothalamic	  neurons,	  we	  
recommend	  performing	  quality	  control	  experiments	  based	  on	  immunostaining	  and	  RT-­‐qPCR	  before	  
performing	   further	   experiments.	   Hypothalamic	   patterning	   can	   be	   gauged	   by	   the	   expression	   of	  
regionally-­‐expressed	  transcription	  factors	  (Figure	  3A	  and	  3B),	  and	  hypothalamic	  neurogenesis	  can	  be	  
confirmed	  by	  testing	  for	  neuropeptides	  that	  are	  highly	  enriched	  in	  the	  hypothalamus	  (Figure	  3C,	  3D,	  
3F)	  (Tables	  1-­‐3).	  	  
	  
Table	  1.	  Proteins	  detectable	  by	  immunofluorescence	  in	  differentiated	  cultures	  by	  Day	  14	  or	  by	  Day	  
40.	  
EXPRESSION	   HYPOTHALAMIC	  NEURONS	   CORTICAL	  NEURONS	  
Day	  14	   FOXG1	  (few	  cells)	  
NKX2.1	  (most	  cells)	  
FOXG1	  (most	  cells)	  	  
NKX2.1	  (few	  cells)	  
OTX1/2	  (many	  cells)	  	  	  
PAX6	  (many	  cells)	  
Day	  40	   TUJ1	  (most	  cells)	   TUJ1	  (most	  cells)	  
MAP2	  (most	  cells)	  
POMC	  (many	  cells)	  
AGRP	  (some	  cells)	  
HCRT	  (some	  cells)	  
PMCH	  (some	  cells)	  
MAP2	  (most	  cells)	  
POMC	  (negative)	  
AGRP	  (negative)	  
TBR1	  (many	  cells)	  
CTIP2	  (many	  cells)	  
	  
Table	  2.	  List	  of	  primary	  antibodies.	  	  
ANTIGEN	   SUPPLIER,	  catalog	  number,	  RRID	   SPECIES	   DILUTION	  
AGRP	  	   Acris	   Antibodies	   GmbH	   Cat#	   GT15023-­‐100	   Lot#	  
RRID:AB_1611787	  
goat	   1:300	  
CTIP2	   Abcam	  Cat#	  ab18465	  Lot#	  RRID:AB_2064130	   rat	   1:500	  
FOXG1	   Santa	   Cruz	   Biotechnology	   Cat#	   sc-­‐18583	   Lot#	  
RRID:AB_2294176	  
goat	   1:100	  
MAP2	   Abcam	  Cat#	  ab5392	  Lot#	  RRID:AB_2138153	   chicken	   1:2,000	  
NKX2.1	   Innovative	   Research	   Cat#	   18-­‐0221	   Lot#	  
RRID:AB_86728	  
mouse	   1:500	  
OTX1/2	   Millipore	  Cat#	  AB9566	  Lot#	  RRID:AB_2157186	   rabbit	   1:300	  
PAX6	   Covance	   Research	   Products	   Inc	   Cat#	   PRB-­‐278P-­‐100	  
Lot#	  RRID:AB_291612	  
rabbit	   1:500	  
POMC	   Thermo	   Fisher	   Scientific	   Cat#	   MA5-­‐16319	   Lot#	  
RRID:AB_2537838	  
mouse	   1:200	  
PMCH	   Sigma-­‐Aldrich	  Cat#	  M8440	  Lot#	  RRID:AB_260690	   rabbit	   1:1,000	  
TBR1	   Abcam	  Cat#	  ab31940	  Lot#	  RRID:AB_2200219	   rabbit	   1:500	  
TUJ1	   BioLegend	  Cat#	  845502	  Lot#	  RRID:AB_2566589	   rabbit	   1:2,000	  
	  
Table	  3.	  Primers	  used	  for	  gene	  expression	  analysis.	  
GENE	   Expected	  




expression	   in	  
cortical	  cultures	  
Taqman	  Assay	  ID	  (Thermo	  Fisher)	  
AGRP	   high	   low	   Hs00361403_g1	  
EMX1	   low	   high	   Hs00417957_m1	  
FOXG1	   low	   high	   Hs01850784_s1	  
NKX2.1	   high	   low	   Hs00968940_m1	  
POMC	   high	   low	   Hs01596743_m1	  
OTP	   high	   low	   Hs01888165_s1	  
SIM1	   high	   low	   Hs00231914_m1	  
	  
Materials	  
-­‐	  Geltrex	  LDEV-­‐Free	  Reduced	  Growth	  Factor	  Basement	  Membrane	  Matrix	  [Thermo	  Fisher	  Scientific,	  
cat.	  no.	  A1413202];	  
-­‐	  Glass	  coverslip	  [Thermo	  Scientific,	  cat.	  no.	  MENZCB00120RAC20];	  
-­‐	  Hydrochloric	  acid	  (HCl)	  [Fisher	  Chemicals,	  cat.	  no.	  MFCD00011324	  –	  2.5	  L];	  
-­‐	  Cultures	  generated	  in	  BASIC	  PROTOCOL	  3;	  
-­‐	   Paraformaldehyde	   [Sigma	   Aldrich,	   cat.	   no.	   158127	   –	   see	   Reagents	   and	   Solutions,	   or	   4%	  
Paraformaldehyde	  in	  PBS,	  Santa	  Cruz,	  cat.	  no.	  30525-­‐89-­‐4];	  
-­‐	  Normal	  Donkey	  Serum	  [Jackson	  Immunoresearch	  Labs	  Inc.,	  cat.	  no.	  017-­‐000-­‐121];	  
-­‐	  Triton	  X-­‐100	  [Sigma	  Aldrich,	  cat.	  no.	  T8787];	  
-­‐	  Tris	  Buffered	  Saline	  (TBS)	  [Sigma	  Aldrich,	  cat.	  no.	  T5030];	  
-­‐	  Primary	  antibodies	  [see	  Reagents	  and	  Solutions,	  Table	  2];	  
-­‐	  4ʹ′,6-­‐Diamidine-­‐2ʹ′-­‐phenylindole	  dihydrochloride	  (DAPI)	  [Sigma	  Aldrich,	  cat.	  no.	  10236276001];	  
-­‐	  Phosphate	  Buffered	  Saline,	  calcium	  and	  magnesium-­‐free	  (DPBS),	  pH	  range	  7.0-­‐7.3	  [Thermo	  Fisher	  
Scientific,	  cat.	  no.	  14190250];	  
-­‐	  ProLong	  Diamond	  Antifade	  Mountant	  [Thermo	  Fisher	  Scientific,	  cat.	  no.	  P36965];	  
-­‐	  RNA	  isolation	  kit	  [Qiagen,	  cat.	  no.	  74104];	  
-­‐	  Primers	  [see	  Reagents	  and	  Solutions,	  Table	  3];	  
-­‐	  Ethanol	  [Sigma	  Aldrich,	  cat.	  no.	  V0T0041]	  [see	  Reagents	  and	  Solutions];	  
-­‐	  Parafilm	  [Sigma	  Aldrich,	  cat.	  no.	  P7793];	  
-­‐	  Sodium	  Azide	  [Sigma	  Aldrich,	  cat.	  no.	  769320]	  [see	  Reagents	  and	  Solutions];	  
-­‐	  Human	  brain	  total	  RNA	  [Thermo	  Fisher	  Scientific,	  cat.	  no.	  AM7962].	  
	  
*	  Equipment:	  
-­‐	  6-­‐well	  plate,	  12-­‐well	  plate,	  24-­‐well	  plate,	  or	  10	  cm	  plate;	  
-­‐	  15	  ml	  V-­‐bottom	  polypropylene	  tube	  (e.g.	  Falcon	  tubes);	  
-­‐	  Pipettes:	  2-­‐10	  µl,	  20-­‐200	  µl,	  100-­‐1000	  µl	  and	  corresponding	  tips;	  
-­‐	  Automated	  pipetman	  and	  serological	  pipettes	  (5	  ml,	  10	  ml,	  25	  ml);	  
-­‐	  Transfer	  pipettes	  [Biologix,	  cat.	  no.	  30-­‐0135A1];	  
-­‐	  Fine	  forceps	  for	  handling	  glass	  coverslips;	  
-­‐	  Chemical	  hood;	  
-­‐	  Adhesive	  film	  [e.g.	  Bio	  Rad,	  cat.	  no.	  MSB1001].	  
	  
Protocol	  steps	  –	  Step	  annotation	  
	  
A-­‐   Prepare	  coverslips	  for	  cell	  plating.	  	  
1-­‐   Incubate	   glass	   coverslips	   in	   5	   M	   HCl	   at	   65°C	   overnight,	   preferably	   in	   a	   rolling	   or	   shaking	  
incubator	  to	  enable	  even	  acid	  etching	  of	  coverslips.	  
2-­‐   Carefully	  remove	  acid	  and	  transfer	  coverslips	  to	  a	  clean	  glass	  beaker.	  	  
3-­‐   Thoroughly	  wash	  cover	  slips	  5x	  with	  large	  volumes	  of	  distilled	  water.	  	  
4-­‐   Cover	  and	  store	  cover	  slips	  in	  70%	  ethanol.	  Cover	  with	  Parafilm.	  	  
5-­‐   In	  a	  class	  II	  Biosafety	  cabinet,	  transfer	  one	  acid-­‐etched	  and	  ethanol-­‐sterilised	  glass	  coverslip	  
per	   well	   of	   a	   24-­‐well	   plate	   using	   a	   sterile	   pair	   of	   forceps.	   Transfer	   a	   sufficient	   number	   of	  
coverslips	   to	   analyse	   desired	   number	   of	   antibodies	   for	   each	   cell	   line	   and	   differentiation	  
protocol,	  keeping	  in	  mind	  biological	  and	  technical	  replicates.	  	  
6-­‐   Once	   coverslips	   have	   completely	   dried,	   coat	   them	   with	   Geltrex	   as	   described	   in	   BASIC	  
PROTOCOL	  1,	  A.	  	  
*	  Note	  -­‐	  At	  this	  point	  it	  is	  useful	  to	  coat	  a	  sufficient	  number	  of	  wells	  with	  Geltrex	  for	  RT-­‐qPCR	  
analysis	  as	  described	  below	  if	  this	  analysis	  is	  to	  be	  carried	  out,	  especially	  for	  analysis	  at	  later	  
time	  points	  such	  as	  Day	  40.	  	  	  
7-­‐   Plate	  differentiated	  neurons,	  dissociated	  as	  described	  in	  BASIC	  PROTOCOL	  3,	  B,	  step	  1-­‐12,	  onto	  
24-­‐well	  plate	  filled	  with	  glass	  cover	  slips.	  
8-­‐   Allow	  cells	  to	  recover	  for	  24-­‐48	  hours.	  
9-­‐   Gently	  aspirate	  medium	  and	  wash	  cells	  with	  PBS,	  taking	  care	  to	  avoid	  cell	  detachment.	  	  
10-­‐  In	  a	  chemical	  hood,	  gently	  add	  4%	  Paraformaldehyde	  (PFA)	  and	  incubate	  cells	  10	  minutes	  at	  
room	  temperature.	  	  
*	  Note	  -­‐	  If	  using	  PFA	  from	  a	  frozen	  stock,	  ensure	  that	  PFA	  is	  completely	  thawed	  but	  not	  warm.	  	  
11-­‐  In	  a	  chemical	  hood,	  collect	  PFA	  for	  waste	  disposal,	  but	  take	  care	  not	  to	  let	  cells	  dry.	  
12-­‐  Wash	  cells	  3	  times	  with	  1	  x	  TBS,	  again	  taking	  care	  not	  to	  let	  cells	  dry.	  	  
*	  Note	  -­‐	  To	  ensure	  gentle	  washing	  of	  cells,	  it	  is	  advisable	  to	  use	  a	  plastic	  transfer	  pipette	  capped	  
with	  a	  P200	  pipette	  tip.	  Fixed	  cells	  can	  be	  stored	  in	  TBS	  at	  this	  point	  at	  4˚C	  for	  up	  to	  72	  hours	  
before	  staining.	  	  
	  
B-­‐   Staining	  
1-­‐   After	  fixing	  cells,	  remove	  TBS	  and	  add	  primary	  antibody	  solution	  (10%	  Normal	  Donkey	  Serum	  
re-­‐suspended	  in	  TBS	  +	  0.1	  %	  Triton	  +	  primary	  antibodies)	  to	  fixed	  cells	  and	  incubate	  them	  at	  
4°C	  overnight	  (see	  Table	  2).	  
2-­‐   Wash	  cells	  with	  1	  x	  TBS,	  3	  times	  briefly	  and	  gently,	  and	  then	  once	  for	  at	  least	  30	  minutes.	  
3-­‐   Add	  secondary	  antibody	  solution	  (10%	  Normal	  Donkey	  Serum	  re-­‐suspended	  TBS	  +	  0.1%	  Triton	  
+	  secondary	  antibodies),	  incubate	  cells	  2h	  at	  room	  temperature.	  
4-­‐   Wash	  cells	  1x	  TBS,	  3	  times	  briefly	  and	  gently,	  and	  then	  once	  for	  at	  least	  30	  minutes.	  
5-­‐   Add	  360	  nM	  DAPI	  solution	  and	  incubate	  cells	  5	  minutes	  at	  room	  temperature	  in	  darkness.	  
6-­‐   Wash	  cells	  3x	  times	  with	  1	  x	  TBS.	  
7-­‐   Store	  plates	  at	  4°C	  in	  TBS	  with	  0.1%	  sodium	  azide,	  protect	  from	  light.	  
*	  Note	  -­‐	  If	  cells	  are	  on	  coverslips,	  mount	  them	  onto	  glass	  slides	  as	  described	  below.	  If	  cells	  are	  
on	  plates,	  add	  an	  appropriate	  volume	  of	  TBS	  with	  0.1%	  sodium	  azide	  for	  the	  size	  of	  the	  well	  
and	  seal	  the	  plate	  with	  adhesive	  film	  to	  prevent	  evaporation.	  	  
	  
C-­‐   Mounting	  slides	  
1-­‐   Add	  1	  drop	  of	  mounting	  medium	  (ProLong	  Diamond	  Antifade	  Mountant)	  onto	  a	  glass	  slide,	  
taking	  care	  to	  avoid	  introducing	  air	  bubbles.	  
2-­‐   Remove	  excess	  liquid	  from	  cover	  slip	  by	  dabbing	  on	  a	  paper	  towel.	  
3-­‐   Place	  cover	  slip	  sample-­‐side	  down	  onto	  mounting	  medium	  on	  the	  glass	  slide.	  
4-­‐   Cure	  for	  24	  hours	  at	  room	  temperature,	  protect	  from	  light.	  
5-­‐   Gently	  clean	  cover	  slips	  with	  70%	  ethanol	  and	  image.	  
	  
D-­‐   Analysis	  of	  cells	  by	  RT-­‐qPCR	  
	  
1-­‐   Collect	   approximately	   1	   x	   106	   cells	   per	   condition	   from	   freshly	   dissociated	   cells	   or	   from	  
adherent	  cultures	  dissociated	  with	  TrypLE	  as	  described	  above.	  
2-­‐   Wash	  and	  pellet	  cells	  as	  described	  above.	  	  
3-­‐   Carefully	  aspirate	  all	  supernatant	  from	  cell	  pellet	  and	  resuspend	  in	  350	  µl	  RLT	  buffer	  from	  the	  
Qiagen	  RNeasy	  Mini	  Kit.	  	  
4-­‐   Isolate	  RNA	  according	  to	  manufacturer’s	  instruction	  using	  the	  Qiagen	  RNeasy	  Mini	  Kit.	  
5-­‐   Analyse	  gene	  expression	  by	  TaqMan	  RT-­‐qPCR	  as	  described	  elsewhere	  (Toyohara	  et	  al.,	  2015).	  
As	  a	  positive	  control,	  we	  use	  commercially	  available	  human	  whole-­‐brain	  RNA	  [See	  materials].	  
	  
SUPPORT	  PROTOCOL	  3	  FURA-­‐2	  IMAGING	  OF	  HYPOTHALAMIC	  CULTURES	  
Calcium	   imaging	   can	   be	   performed	   on	   hPSC-­‐derived	   hypothalamic	   neurons,	   allowing	   for	  
functional	  physiological	  analysis	  of	  multiple	  neurons	  in	  parallel.	  Compared	  to	  conventional	  whole	  cell	  
electrophysiology,	  calcium	  imaging	  enables	  the	  analysis	  of	  larger	  cell	  numbers	  in	  a	  shorter	  amount	  of	  
time,	  albeit	  with	  lower	  temporal	  precision	  or	  insights	  into	  cellular	  membrane	  properties.	  A	  number	  of	  
different	  calcium	  indicators	  are	  available	  for	  different	  applications	  (Russell,	  2011;	  Ikegaya	  et	  al.,	  2005).	  
We	  describe	  here	  the	  use	  of	  the	  bulk-­‐loaded	  ratiometric	  indicator	  Fura-­‐2AM,	  which	  should	  be	  broadly	  
applicable.	  Ratiometric	  indicators	  minimise	  the	  effects	  of	  photobleaching	  and	  other	  artefacts	  such	  as	  
uneven	  loading	  into	  cells.	  Fura-­‐2AM	  fluoresces	  more	  brightly	  at	  340	  nm	  and	  more	  weakly	  at	  380	  nm	  
in	   the	   presence	   of	   calcium,	   enabling	   the	   340:380	   nm	   fluorescence	   intensity	   ratio	   of	   Fura20AM	   to	  
indicate	  changes	  in	  intracellular	  calcium	  levels	  (Takahashi	  et	  al.,	  1999).	  In	  cultures	  at	  least	  30	  days	  old,	  
calcium	  imaging	  can	  be	  used	  to	  investigate	  how	  the	  hPSC-­‐derived	  neurons	  respond	  to	  stimuli.	  Neurons	  
older	  than	  Day	  50	  tend	  to	  be	  more	  active,	  and	  are	  better	  suited	  to	  studying	  synaptic	  activity	  (Kirwan	  
et	  al.,	  2015;	  Shi	  et	  al.,	  2012;	  Prè	  et	  al.,	  2014).	  	  
	  
Materials:	  	  
-­‐	  Geltrex	  LDEV-­‐Free	  Reduced	  Growth	  Factor	  Basement	  Membrane	  Matrix	  [Thermo	  Fisher	  Scientific,	  
cat.	  no.	  A1413202];	  
-­‐	   hPSC-­‐derived	   hypothalamic	   neurons	   Day	   30+	   (preferably	   Day	   40-­‐Day	   60)	   [generated	   in	   BASIC	  
PROTOCOL	  3];	  
-­‐	  TrypLE	  Express	  1X,	  no	  phenol	  red	  [Thermo	  Fisher	  Scientific,	  cat.	  no.	  12604021];	  
-­‐	  DMEM/F12	  without	  phenol	  red	  [Thermo	  Fisher	  Scientific,	  cat.	  no.	  21041025];	  
-­‐	  Artificial	  cerebrospinal	  fluid	  (ACSF)	  [see	  Reagents	  and	  Solutions];	  
-­‐	  Fura2-­‐AM	  [Fisher	  Scientific,	  cat.	  no.	  	  F1221];	  
-­‐	  Dimethyl	  Sulfoxide,	  DMSO	  [Sigma	  Aldrich,	  cat.	  no.	  D2650-­‐100ml];	  
-­‐	  Pluronic	  F127	  [Sigma-­‐Aldrich,	  cat.	  no.	  P2443];	  
-­‐	  Papain	  [cat.no.].[Thermo	  Fisher	  Scientific,	  cat	  no.	  88290];	  
	  
*	  Equipment:	  
-­‐	  35	  mm	  Ibidi	  dishes	  [Thistle	  Scientific,	  cat.	  no.	  80136];	  
-­‐	  37°C,	  5%	  CO2	  humidified	  incubator;	  
-­‐	  Class	  II	  biosafety	  cabinet;	  
-­‐	  Pipettes	  2-­‐10	  µl,	  20-­‐200	  µl,	  100-­‐1000	  µl	  and	  corresponding	  tips;	  
-­‐	  Automated	  pipetman	  and	  serological	  pipettes	  (5	  ml,	  10	  ml,	  25	  ml);	  
-­‐	  Inverted	  microscope,	  e.g.	  Eclipse	  TE2000U	  (Nikon)	  
-­‐	  Epifluorescence	  illuminator	  and	  monochromator	  to	  provide	  excitation	  wavelengths	  at	  340	  nm,	  360	  
nm,	  380	  nm.	  e.g.	  Optoscan	  (Cairn	  Research	  Ltd);	  
-­‐	  Emission	  filter:	  510nm;	  
-­‐	  Objective:	  40x	  Nikon	  Oil	  immersion,	  N.A.	  1.3;	  
-­‐	  EMCCD	  camera,	  e.g.	  Orca-­‐ER-­‐1394	  (Hamamatsu)	  
-­‐	  Perfusion	  system;	  we	  use	  a	  custom-­‐built	  gravity	  perfusion	  system,	  however	  commercial	  systems	  are	  
available,	  e.g.	  MPS-­‐2	  (World	  Precision	  Instruments);	  
-­‐	  Imaging	  Software:	  e.g.	  Metafluor	  (Molecular	  devices,	  RRID:	  SCR_014294);	  	  
	  
Protocol	  steps	  –	  Step	  annotation	  
A-­‐   Preparation	  of	  cells	  for	  Calcium	  imaging.	  
1-­‐   Seed	  neurons	  at	  1	  x	  105	  cells	  per	  cm2	  onto	  Geltrex	  coated	  35	  mm	  Ibidi	  dishes	  using	  Papain	  
with	  TrypLE	  (see	  Basic	  Protocol	  3,	  step	  14).	  	  
*	  Note	  -­‐	  Cells	  can	  be	  imaged	  as	  soon	  as	  24	  hours	  after	  plating	  onto	  35	  mm	  dishes,	  depending	  
on	  the	  experiment.	  To	  detect	  spontaneous	  and	  synaptic	  activity,	  it	  is	  recommended	  that	  cells	  
are	  allowed	  to	  recover	  for	  at	  least	  1	  week	  after	  plating.	  	  
2-­‐   Aspirate	  culture	  media	  from	  cells	  and	  add	  1	  ml	  of	  Fura2-­‐AM	  of	  loading	  solution	  per	  35	  mm	  
dish	  (Figure	  4A).	  	  
3-­‐   Transfer	  cells	  to	  tissue	  culture	  incubator	  at	  37˚C	  and	  5%	  CO2	  for	  45	  minutes.	  	  
4-­‐   Remove	  loading	  solution	  from	  the	  cells	  and	  wash	  2	  times	  with	  ACSF.	  	  	  
5-­‐   Transfer	  cells	  to	  incubator	  for	  a	  further	  30	  minutes	  before	  imaging.	  	  	  
	  
B-­‐   Calcium	  Imaging	  	  	  	  	  	  	  	  
1-­‐   If	  perfusion	  is	  required,	  prepare	  during	  the	  final	  incubation	  after	  loading	  the	  cells	  with	  Fura2-­‐
AM.	  Setup	  so	  that	  perfusion	  flows	  at	  a	  rate	  of	  50	  µl	  per	  second.	  Turn	  on	  heating	  if	  required.	  	  
*	  Note	  -­‐	  If	  studying	  synaptic	  activity,	  it	  is	  recommended	  that	  cells	  are	  recorded	  at	  37˚C.	  	  
2-­‐   Transfer	  cells	  to	  imaging	  setup	  and	  begin	  perfusion	  of	  ACSF	  onto	  cells.	  Allow	  10	  minutes	  for	  
perfusion	  and	  temperature	  to	  stabilise.	  	  
3-­‐   Check	  for	  fluorescence	  under	  UV	  illumination.	  	  
4-­‐   Navigate	  to	  a	  field	  where	  the	  cell	  density	  allows	  for	  clear	  resolution	  of	  single	  cells	  and	  which	  
also	  enables	  the	  measurement	  of	  background	  intensity	  (Figure	  4B)	  	  
5-­‐   Use	  software	  to	  set	  up	  acquisition	  at	  340	  nm,	  360	  and	  380	  nm	  excitation,	  and	  detection	  of	  
emitted	  light	  at	  515	  nm.	  
*	  Note:	   The	   360	   nm	   channel	   is	   used	   to	   determine	   the	   extent	   to	  which	   photobleaching	   is	  
occurring.	  This	   is	  done	  comparing	  the	   first	  and	   last	   image	   in	   the	  360	  nm	  channel	   from	  the	  
dataset,	  checking	  whether	  fluorescence	  intensity	  was	  lost	  during	  the	  experiment.	  
6-­‐   Focus	  the	  cells	  and	  adjust	  the	  gain	  and	  exposure	  settings	  so	  that	  the	  signal	  is	  not	  saturated.	  
We	  recommend	  exposures	  of	  50-­‐200	  milliseconds	  to	  minimise	  bleaching.	  	  
7-­‐   Use	  the	  imaging	  software	  to	  highlight	  cell	  bodies	  of	  interest	  and	  a	  background	  area.	  Use	  the	  
background	  area	  to	  perform	  a	  background	  signal	  subtraction.	  	  	  
*	  Note	  -­‐	  Observations	  of	  neuronal	  activity	  and	  background	  subtraction	  can	  also	  be	  performed	  
post-­‐acquisition	  by	  exporting	  the	  acquired	  image	  sets	  using	  commercial	  software	  or	  custom	  
scripts	  (e.g.	  MATLAB,	  RRID,	  SCR_001622).	  	  
8-­‐   Acquire	   time-­‐lapse	   recordings	  at	  1-­‐10	  Hz	  depending	  on	   the	  experiment.	  Generally,	  activity	  
that	   produces	   subtle,	   fast	   changes	   in	   calcium	   influx	   should	   be	   recorded	   at	   10	   Hz,	   while	  
activities	  that	  produce	  large,	  robust	  calcium	  influxes	  can	  be	  recorded	  at	  1	  Hz.	  	  The	  length	  of	  
recording	  will	   depend	  on	   the	   application,	   i.e.	   drug	  perfusions,	   number	   of	   treatments,	   and	  
latency	  of	  response,	  but	  is	  typically	  30-­‐50	  minutes.	  
9-­‐   Near	  the	  end	  of	  each	  recording,	  perfuse	  cultures	  with	  ACSF	  containing	  30	  mM	  KCl.	  This	  will	  
depolarise	  the	  cells	  and	  act	  as	  a	  benchmark	  for	  the	  electrical	  maturity	  and	  general	  health	  of	  
the	  cells.	  An	  example	  recording	  is	  shown	  in	  Figure	  4C.	  	  
	  
REAGENTS	  AND	  SOLUTIONS	  (in	  alphabetical	  order)	  
	  
ACSF	  
•   129	  mM	  NaCl	  [Sigma	  Aldrich,	  cat.	  no.	  31434],	  
•   5	  mM	  KCl	  [Sigma	  Aldrich,	  cat.	  no.	  31248],	  
•   1	  mM	  CaCl2	  [Sigma	  Aldrich,	  cat.	  no.	  C5670],	  
•   1	  mM	  MgCl2	  [Promega,	  cat.	  no.	  A3511],	  
•   25	  mM	  HEPES	  [Thermo	  Fisher	  Scientific,	  cat.	  no.	  15630056],	  
•   11.1	  mM	  Glucose	  [Sigma	  Aldrich,	  cat.	  no.	  G7021],	  
Check	  that	  pH	  is	  7.2-­‐7.4	  and	  adjust	  if	  necessary.	  
*	  Note	  -­‐	  Stock	  solutions	  of	  each	  reagent	  are	  made	  up	  in	  sterile	  distilled	  water.	  
	  
ACSF,	  30	  mM	  KCl	  
•   104	  mM	  NaCl	  [Sigma	  Aldrich,	  cat.	  no.	  31434],	  	  
•   30	  mM	  KCl	  [Sigma	  Aldrich,	  cat.	  no.	  31248],	  	  
•   1	  mM	  CaCl2	  [Sigma	  Aldrich,	  cat.	  no.	  C5670],	  
•   1	  mM	  MgCl2	  [Promega,	  cat.	  no.	  A3511],	  
•   25	  mM	  HEPES	  [Thermo	  Fisher	  Scientific,	  cat.	  no.	  15630056],	  
•   11.1	  mM	  Glucose	  [Sigma	  Aldrich,	  cat.	  no.	  G7021],	  
Check	  that	  pH	  is	  7.2-­‐7.4	  and	  adjust	  if	  necessary.	  
*	  Note	  -­‐	  Stock	  solutions	  of	  each	  reagent	  are	  made	  up	  in	  sterile	  distilled	  water.	  
	  
BDNF	  
Reconstitute	  powder	  in	  DPBS	  with	  0.1%	  BSA	  (sterile	  filtered)	  to	  100	  µg/ml,	  aliquot,	  and	  store	  
aliquots	  at	  -­‐80°C.	  Use	  at	  1:1,000	  for	  a	  10	  ng/ml	  final	  concentration.	  
	  
DAPI	  
Reconstitute	   powder	   in	   sterile	   distilled	   water	   to	   360	   µM	   (1	   µg/ml)	   (in	   the	   dark	   at	   room	  
temperature)	  and	  store	  aliquots	  at	  -­‐20°C.	  Use	  at	  1:10,000	  for	  a	  360	  nM	  final	  concentration.	  
	  
DAPT	  
Reconstitute	  powder	  in	  DMSO	  to	  generate	  a	  50	  mM	  stock,	  aliquot,	  and	  store	  aliquots	  at	  -­‐20°C.	  
Use	  at	  1:10,000	  for	  a	  5	  µM	  final	  concentration.	  
	  
EDTA	  
Purchased	  at	  a	  stock	  concentration	  of	  0.5	  M.	  Dilute	  1:1,000	  in	  tissue	  culture	  grade	  Ca2+	  and	  
Mg2+	  free	  PBS	  and	  sterile	  filter.	  Store	  at	  room	  temperature	  or	  at	  4°C	  for	  up	  to	  a	  year.	  	  
	  
Ethanol	  70%	  (100	  ml)	  
•   30	  ml	  sterile	  distilled	  water,	  
•   70	  ml	  ethanol	  (technical	  grade	  99%)	  
	  
FGF2	  
Reconstitute	  powder	  according	   to	  manufacturer’s	  directions	   to	  generate	  a	  20	  ng/ml	  stock,	  
aliquot,	  and	  store	  aliquots	  at	  -­‐80°C.	  	  
	  
Fura2	  
Prepare	  Fura2-­‐AM	  stock	  by	  dissolving	  50	  µg	  in	  48	  µl	  DMSO	  and	  2	  µl	  10%	  w/v	  pluronic	  acid.	  
This	  will	  give	  a	  1	  mM	  stock	  solution.	  Aliquot	  and	  freeze	  at	  -­‐20˚C.	  	  
	  
Fura2	  Loading	  solution	  
Add	  1	  µl	  of	  1	  mM	  Fura2-­‐AM	  stock	  per	  3	  ml	  of	  ACSF	  (final	  concentration	  of	  333	  nM).	  Prepare	  
1ml	  per	  35	  mm	  dish	  to	  be	  loaded.	  
	  
hPSC	  wash	  medium	  (30	  ml)	  
•   30	  ml	  mTeSR1,	  
•   30	   µl	   Y-­‐27632	   dihydrochloride	   Rock	   inhibitor	   stock	   solution	   (1000x)	   to	   a	   final	  
concentration	  of	  10	  µM,	  
•   1	  vial	  D2	  DNAse	  [Worthington,	  cat.	  no	  LK003170].	  
	  
LDN-­‐193189	  
Reconstitute	  powder	   in	  DMSO	  according	   to	  manufacturer’s	  directions	   to	  generate	  a	  1	  mM	  
stock,	  aliquot,	  and	  store	  aliquots	  at	  -­‐20°C.	  Use	  at	  1:10,000	  for	  a	  100	  nM	  final	  concentration.	  
	  
Maturation	  Medium	  (MAT)	  (1	  L)	  
•   1	  L	  N2B27	  medium,	  
•   BDNF	  to	  a	  final	  concentration	  of	  10	  ng/ml,	  added	  fresh	  at	  each	  feeding.	  
	  
mTeSR1	  (0.5	  L)	  
•   400	  ml	  mTeSR1	  medium,	  [STEMCELL	  Technologies,	  cat.	  no	  05851],	  
•   100	  ml	  mTeSR1	  5x	  Supplements,	  [STEMCELL	  Technologies,	  cat.	  no	  05852].	  
	  
N2B27	  (1.07	  L)	  
•   500	  ml	  Neurobasal-­‐A,	  (LS),	  [Thermo	  Fisher	  Scientific,	  cat.	  no	  10888022],	  
•   500	  ml	  DMEM/F12	  with	  GlutaMAX,	  (LS),	  [Thermo	  Fisher	  Scientific,	  cat.	  no	  31331093],	  
•   10	  ml	  Glutamax,	  [Thermo	  Fisher	  Scientific,	  cat.	  no	  35050038],	  
•   10	  ml	  Sodium	  Bicarbonate,	  [Thermo	  Fisher	  Scientific,	  cat.	  no	  25080-­‐094],	  
•   5	  ml	  MEM	  Nonessential	  Amino	  Acids,	  [Thermo	  Fisher	  Scientific,	  cat.	  no	  11140035],	  
•   1	  ml	  Ascorbic	  Acid	  (200	  mM,	  use	  1:1,000),	  [Sigma	  Aldrich,	  cat.	  no	  A4403],	  
•   10	  ml	  Penicillin-­‐Streptomycin	  [Thermo	  Fisher	  Scientific,	  cat.	  no.	  15140122],	  
Sterile	  filter,	  then	  add	  the	  following	  supplements:	  	  
•   20	  ml	  B27	  supplement	  (x50),	  [Thermo	  Fisher	  Scientific,	  cat.	  no	  17504044],	  
•   10	  ml	  N2	  supplement	  (x100),	  [Thermo	  Fisher	  Scientific,	  cat.	  no	  17502048].	  
	  
Papin	  with	  TrypLE	  








Reconstitute	  powder	  in	  DMSO	  to	  generate	  a	  10	  mM	  stock,	  aliquot,	  and	  store	  aliquots	  at	  -­‐80°C.	  
Use	  at	  1:10,000	  for	  a	  1	  µM	  final	  concentration.	  	  
	  
SB431542	  
Reconstitute	  powder	  in	  DMSO	  to	  generate	  a	  10	  mM	  stock,	  aliquot,	  and	  store	  aliquots	  at	  -­‐80°C.	  
Use	  at	  1:1,000	  for	  a	  10	  µM	  final	  concentration.	  	  
	  
Sodium	  Azide:	  
Dissolve	  sodium	  azide	  powder	  to	  10%	  w/v	  in	  distilled	  water.	  Make	  to	  0.1%	  w/v	  by	  diluting	  1	  
in	  100	  in	  TBS.	  
	  
Smoothed	  agonist	  (SAG)	  
Reconstitute	  powder	  in	  DMSO	  to	  generate	  a	  10	  mM	  stock,	  aliquot,	  and	  store	  aliquots	  at	  -­‐80°C.	  
Use	  at	  1:10,000	  for	  a	  1	  µM	  final	  concentration.	  	  
	  
TBS	  (Tris	  buffered	  saline)	  
Dissolve	  the	  tablets	  in	  sterile	  distilled	  water	  according	  to	  manufacturer’s	  directions,	  adjust	  the	  
pH	  value	  to	  7.4	  with	  Hydrochloric	  acid.	  
	  
Trituration	  medium	  (30	  ml)	  
•   30	  ml	  Maturation	  medium,	  
•   30	   µl	   Y-­‐27632	   dihydrochloride	   Rock	   inhibitor	   stock	   solution	   (1,000x)	   to	   a	   final	  
concentration	  of	  10	  µM,	  
•   1	  vial	  D2	  DNAse	  [Worthington,	  cat.	  no	  LK003170].	  
	  
XAV939	  
Reconstitute	  powder	  in	  DMSO	  according	  to	  manufacturer’s	  directions	  to	  generate	  a	  10	  mM	  
stock,	  aliquot,	  and	  store	  aliquots	  at	  -­‐20°C.	  Use	  at	  1:5,000	  for	  a	  2	  µM	  final	  concentration.	  
	  
Y-­‐27632	  dihydrochloride	  Rock	  inhibitor	  
Reconstitute	  powder	  in	  sterile	  distilled	  water	  to	  generate	  a	  10	  mM	  stock,	  aliquot,	  and	  store	  
aliquots	  at	  -­‐20°C.	  Use	  at	  1:1,000	  for	  a	  10	  µM	  final	  concentration.	  
	  
DISCUSSION	  
The	  aim	  of	  this	  collection	  of	  protocols	   is	  to	  enable	  research	  groups	  with	  adequate	  facilities	  
and	  expertise	  to	  generate	  hPSC-­‐derived	  hypothalamic	  neurons.	  Complemented	  with	  in	  vivo	  validation	  
in	   animal	  models,	   the	   utility	   of	   this	   hPSC-­‐system	   should	   prove	   a	   powerful	   tool	   to	   study	   the	   basic	  
biology	   of	   hypothalamic	   neurons	   and	   to	   model	   diseases	   of	   hypothalamic	   origin	   with	   the	   aim	   of	  
developing	  improved	  treatments.	  
A	  principal	  advantage	  of	  this	  culture	  system	  is	  its	  scalability.	  Since	  each	  10	  cm	  plate	  of	  stem	  
cells	   yields	  ~1	  x	  108	  neurons	  or	  more,	  even	  neuron	   types	   that	  are	  produced	   relatively	   inefficiently	  
(~1%)	   can	   be	   produced	   in	   large	   numbers	   (~1	   x	   106	   per	   plate).	   This	   enables	   human	   hypothalamic	  
neurons	  to	  be	  deeply	  characterised,	  used	  in	  disease	  modelling	  studies,	  and	  studied	  in	  high-­‐throughput	  
imaging	   assays	   and	   analyses,	   paving	   the	   way	   for	   small	   molecules	   screens	   for	   modulators	   of	  
hypothalamic	  neuron	  activity	  and	  function.	  
Depending	  on	  the	  application,	  experiments	  can	  be	  carried	  out	  at	  relatively	  early	  time	  points.	  
For	  example,	  many	  hypothalamic	  neurons	  generated	  by	  this	  protocol	  respond	  to	  depolarising	  stimuli	  
as	  early	  as	  D30	  (unpublished	  observations).	  This	  allows	  for	  the	  study	  of	  certain	  cell-­‐intrinsic	  responses	  
in	  contrast	  to	  other	  culture	  system	  in	  which	  electrophysiological	  maturation	  can	  take	  several	  months	  
(Hartfield	  et	  al.,	  2014;	  Kirwan	  et	  al.,	  2015;	  Shi	  et	  al.,	  2012).	  	  
Another	   key	   advantage	   of	   the	   hPCS	   system	   is	   the	   ability	   to	   perform	   gene	   editing	   using	  
CRISPR/Cas9	   (Cong	   et	   al.,	   2013;	   Santos	   et	   al.,	   2016).	   Gene-­‐editing	   technology	   should	   provide	   a	  
powerful	   platform	   to	   probe	   key	   aspects	   of	   human	   hypothalamic	   biology	   and	   for	   investigating	   the	  
mechanisms	  of	  metabolic	  disorders.	  	  Together,	  these	  techniques	  could	  allow	  for	  a	  robust	  investigation	  
of	  the	  molecular	  and	  cellular	  pathways	  that	  are	  important	  for	  hypothalamic	  health	  and	  disease.	  	  
	  	  
Critical	  parameters	  
hPSC	  culture:	   It	   is	   critical	   that	  hPSCs	  are	  passaged	   routinely	  and	  are	  not	  allowed	   to	  become	  over-­‐
confluent	   or	   to	   become	   contaminated	   with	   differentiated	   cells.	   Since	   hPSCs	   accumulate	   genetic	  
defects	  over	  time	  in	  culture	  (Amps	  et	  al.,	  2011;	  Merkle	  et	  al.,	  2017;	  Ronen	  and	  Benvenisty,	  2012)	  it	  is	  
advisable	  to	  use	  cell	  lines	  with	  low	  to	  moderate	  passage	  number	  (<P50).	  Avoid	  splitting	  cells	  at	  ratios	  
exceeding	   1:10,	   as	   sharp	   reductions	   in	   the	   size	   of	   a	   cell	   population	   which	   can	   lead	   to	   unwanted	  
selection	  events.	  We	  also	  recommend	  working	  with	  cell	   lines	  that	  have	  been	  rigorously	  genetically	  
characterised	  by	   sequencing,	  and	   to	   routinely	   karyotype	  and/or	   sequence	  cell	   lines	   to	   test	   for	   the	  
acquisition	  of	  unwanted	  mutations.	  
Cell	  density	  and	  feeding	  frequency:	  A	  major	  cause	  of	  cell	  death	  or	  poor	  differentiation	  can	  be	  cell	  
overgrowth	  or	  inadequate	  nutrient	  availability.	  First,	  ensure	  that	  initial	  plating	  densities	  are	  accurate	  
by	  using	  automated	  cell	  counters	  that	  adjust	  for	  the	  number	  of	  live	  cells.	  There	  is	  some	  variability	  in	  
growth	  rate	  between	  cell	  lines.	  The	  protocols	  described	  here	  should	  be	  appropriate	  for	  most	  cell	  lines,	  
but	  if	  you	  notice	  significant	  cell	  death	  or	  that	  your	  media	  visibly	  acidifies	  within	  24	  hours	  if	  phenol	  red	  
is	  present	  as	  an	  indicator,	  feed	  cells	  more	  frequently	  or	  with	  larger	  media	  volumes.	  	  
Cell	  passaging:	  Cell	  passaging	  can	  be	  a	  major	  source	  of	  cell	  death.	  It	  is	  essential	  to	  gently	  handle	  cells	  
when	  mechanically	  triturating	  them,	  particularly	  stem	  cells	  and	  neurons.	  Minimise	  the	  formation	  of	  
bubbles	  by	  aspirating	  and	  dispelling	  less	  than	  the	  full	  media	  volume.	  Do	  not	  use	  excessive	  force	  when	  
pipetting,	  and	  ensure	  that	  cells	  easily	  wash	  off	  of	  the	  plate	  before	  attempting	  to	  dissociate	  the	  culture,	  
increasing	  the	  time	  that	  cells	  are	  incubated	  in	  EDTA,	  TrypLE,	  or	  TrypLE+Papain,	  if	  necessary.	  Ensure	  
that	  DNase	  is	  present	  in	  the	  trituration	  medium.	  	  
	  
Troubleshooting	  
Poor	  neural	  specification:	  	  At	  Day	  10	  to	  Day	  14,	  the	  majority	  of	  cells	  (above	  80%)	  should	  stain	  positive	  
for	   the	  ventral	   forebrain	  progenitor	   transcription	   factor	  NKX2.1.	  Between	  Day	  15	  and	  30,	  neurons	  
should	  become	  the	  dominant	  cell	  type	  in	  the	  cultures.	  If	  this	  is	  not	  the	  case,	  there	  was	  likely	  a	  defect	  
in	  neuronal	  patterning	  and	  specification.	  The	  likely	  causes	  are:	  	  
1.   Poor	  quality	  or	  differentiated	  hPSCs:	  Make	  sure	  that	  hPSCs	  are	  maintained	  appropriately,	  lack	  
differentiated	  cells,	  and	  are	  in	  rapid	  growth	  phase	  when	  they	  are	  dissociated	  and	  plated	  for	  
differentiation	  (refer	  to	  Critical	  Parameters	  and	  BASIC	  PROTOCOL	  1)	  
2.   Low	  starting	  density:	  Make	  sure	  the	  density	  of	  hPSCs	  is	  not	  less	  than	  60%.	  
3.   Reagent	  problem:	  Make	  sure	  the	  differentiation	  media	  is	  fresh.	  Avoid	  using	  N2B27	  medium	  
older	  than	  2	  weeks.	  Add	  small	  molecule	   inhibitors	  and	  recombinant	  proteins	  on	  the	  day	  of	  
use.	  Avoid	  repeated	  freeze-­‐thaw	  cycles	  of	  aliquots	  and	  other	  reagents.	  
Cell	   detachment:	   Detachment	   can	   sometimes	   occur	   during	   the	   early	   phase	   of	   hypothalamic	  
differentiation.	   Ensure	   that	   cell	   density	   is	   approximately	   75%	   confluence	   when	   Day	   0	   medium	   is	  
added.	  Poor	  Geltrex	  coating	  can	  also	  result	  in	  detachment.	  Make	  sure	  Geltrex	  is	  always	  thawed	  at	  4˚C	  
and	   generate	   single-­‐use	   aliquots.	   Do	   not	   use	   Geltrex	   that	   contains	   visible	   clumps,	   and	   use	   plates	  
immediately	  after	  coating.	  Detachment	  can	  also	  occur	  in	  older	  cultures	  (>	  Day	  50).	  Make	  sure	  that	  the	  
density	   at	   the	   terminal	   plating	   is	   not	   below	  5	   x	   104	   cells	   per	   cm2,	   or	   above	   2	   x	   105	   cells	   per	   cm2.	  
Dissociate	  and	  re-­‐plate	  cells	  if	  necessary	  with	  TrypLE+Papain.	  	  
	  Neurons	  do	  not	  attach	  after	  passaging:	  Make	  sure	  TrypLE	  is	  fully	  washed	  out,	  since	  residual	  enzyme	  
can	  prevent	  attachment.	  Ensure	  that	  plates	  are	  properly	  coated	  with	  Geltrex	  (see	  above).	  If	  plating	  on	  
glass,	  make	  sure	  the	  glass	   is	  thoroughly	  acid-­‐etched.	  Poor	  neuronal	  survival	  can	  also	   indicate	  over-­‐
digestion	  in	  TrypLE	  or	  TrypLE/papain,	  or	  rough	  mechanical	  dissociation	  (see	  Critical	  Parameters).	  	  
	  Contaminating	   cell	   types	   during	   differentiation:	   Some	   non-­‐neuronal	   cell-­‐types	   can	   undergo	  
significant	   proliferation	   and	   become	   dominant	   in	   older	   cultures.	   If	   this	   is	   the	   case	   based	   on	  
immunostaining	  and	  phase	  contrast	  microscopy,	  extend	  DAPT-­‐treatment	  to	  Day	  20.	  Avoid	  passaging	  
cultures	  older	  than	  Day	  40	  if	  possible,	  as	  neurons	  survive	  passaging	  best	  before	  Day	  30	  whereas	  non-­‐
neuronal	  cell-­‐types	  will	  preferentially	  survive	  passaging,	  even	  in	  older	  cultures.	  Avoid	  re-­‐plating	  cells	  
below	  5	  x	  104	  cells	  per	  cm2.	  Neurons	  can	  also	  be	  purified	  by	  FACS	  if	  a	  reporter	  line	  is	  available,	  or	  using	  
a	  neuron-­‐specific	  antigen	  such	  a	  NCAM.	  	  
Cell	  death	  in	  older	  cultures:	  When	  cell	  density	  increases,	  particularly	  as	  the	  cultures	  become	  older,	  
the	  culture	  media	  can	  acidify	  and	  become	  depleted	  of	  nutrients.	  Feed	  cultures	  daily	  or	  with	  a	  larger	  
media	  volume,	  or	  re-­‐plate	  if	  necessary.	  	  
	  
Statistical	  analysis	  	  	  
To	  allow	  for	  thorough	  statistical	  analysis,	  all	  experiments	  are	  performed	  with	  a	  minimum	  of	  
three	  replicate	  wells.	   In	  addition,	  experiments	  should	  be	  repeated	   in	   independent	  differentiations,	  
preferably	  with	  3	  genetically	  distinct	  cell	  lines.	  The	  statistical	  analysis	  performed	  will	  vary	  depending	  
on	  the	  experimental	  design.	  	  
	  
Understanding	  results	  
If	   the	  procedures	  for	  quality	  control	  are	  followed,	   it	  should	  be	  straightforward	  for	  users	  to	  
determine	  if	  they	  have	  succeeded	  in	  generating	  hypothalamic	  neurons.	  Although	  the	  degree	  to	  which	  
stem	  cell-­‐derived	  hypothalamic	  neurons	  accurately	  mimic	  their	  in	  vivo	  counterparts	  has	  yet	  to	  be	  fully	  




Expanding	   hPSCs	   for	   differentiation	   typically	   takes	   1-­‐2	   weeks.	   Differentiation	   to	   NKX2.1	  
positive	  progenitors	  takes	  8-­‐10	  days.	  Hypothalamic	  neurons	  are	  generated	  after	  14-­‐20	  days.	  POMC	  
immunopositive	   cells	  are	   clearly	  visibly	  by	  D25.	  Functional	   studies	   such	  as	   calcium	   imaging	  can	  be	  
carried	  out	  as	  soon	  as	  D30,	  although	  further	  culturing	  cells	  to	  D60	  may	  increase	  neuronal	  maturation	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  Figure	  1:	  hPSC	  culture	  and	  maintenance.	  (A)	  HPSCs	  at	  80%	  confluence	  before	  passaging.	  (B)	  After	  brief	  
incubation	  in	  EDTA,	  the	  edges	  of	  the	  colonies	  begin	  to	  detach,	  taking	  on	  a	  phase	  bright	  appearance	  
(arrows).	  (C)	  40x	  magnification	  image	  of	  a	  hPSC	  colony	  before	  passaging.	  (D)	  After	  incubation	  in	  EDTA,	  
borders	  between	  individual	  hPSCs	  should	  become	  clear,	  phase	  bright,	  and	  well-­‐separated.	  (E)	  HPSCs	  
on	  the	  day	   following	  a	  passage,	   showing	  a	   typical	  density	  after	  passaging.	  Note	   that	  hPSCs	  extend	  
more	  processes	  in	  the	  presence	  of	  Rock	  inhibitor,	  Y-­‐27632,	  giving	  colonies	  a	  jagged	  appearance.	  (G)	  
Colonies	  acquire	  smoother	  borders	  upon	  withdrawal	  of	  Y-­‐27632	  the	  following	  day.	  (H)	  Expansion	  of	  
hPSC	  colonies	  is	  evident	  2	  days	  after	  passaging.	  Colonies	  of	  undifferentiated	  hPSCs	  should	  have	  cells	  
that	  are	  uniform	  in	  morphology.	  
	   	  
	  
	  
Figure	   2:	   Differentiation	   of	   hPSCs	   to	   hypothalamic	   neurons.	   (A)	   Schematic	   of	   hypothalamic	  
differentiation	  protocol.	  (B,B’)	  Dissociated	  hPSCs	  that	  were	  plated	  at	  a	  concentration	  of	  1	  x	  105	  cells	  
per	  cm2	  on	  Day	  1	  should	  be	  at	  approximately	  75%	  on	  Day	  0.	  Differentiation	  medium	  (N2B27)	  with	  
SMAD	  inhibitors	  (10	  μM	  SB431542,	  100	  nM	  LDN193189)	  and	  a	  Wnt	  inhibitor	  (2	  μM	  XAV939)	  is	  then	  
added	   to	   induce	   a	   forebrain	   fate.	   (C,	   C’)	   Cultures	   should	   reach	   confluence	   and	   adopt	   a	   uniform	  
appearance	  by	  Day	  1.	  (D,	  D’)	  By	  Day	  4,	  cell	  density	  is	  dramatically	  increased	  but	  cells	  are	  still	  largely	  a	  
single	  adherent	  layer.	  The	  concentrations	  of	  the	  SMAD	  inhibitors	  and	  Wnt	  inhibitors	  are	  reduced	  to	  
75%,	  50%	  and	  25%	  of	  the	  Day	  0-­‐4	  concentration	  on	  Days	  4-­‐6,	  6-­‐8	  and	  8-­‐10	  respectively	  and	  cultures	  
are	  ventralised	  from	  Day	  2-­‐8	  by	  adding	  1	  μM	  Smoothened	  Agonist	  (SAG)	  and	  1	  μM	  Purmorphamine	  
(Pur).	   (E,	   E’)	   By	   Day	   8,	   cultures	   adopt	   a	   clear	   neuroepithelial	   morphology,	   as	   evidenced	   by	   the	  
formation	  of	  neural-­‐ridge	   like	  structures	   (arrows).	  At	   this	   time	  point,	  5	  μM	  of	   the	  NOTCH	   inhibitor	  
DAPT	  is	  added	  until	  Day	  14	  to	  encourage	  neurogenesis.	  (F,	  F’)	  On	  Day	  14,	  cultures	  have	  become	  over-­‐
confluent	   with	   progenitors	   and	   newborn	   neurons,	   and	   are	   passaged	   1:3.	   At	   this	   time	   point,	   it	   is	  
prudent	  to	  plate	  a	  fraction	  of	  the	  differentiated	  cells	  in	  a	  24-­‐well	  plate	  for	  quality	  control.	  After	  Day	  
14,	  cells	  are	  maintained	  in	  maturation	  media:	  N2B27	  supplemented	  at	  each	  feeding	  with	  10	  ng/mL	  
BDNF.	   (G,	  G’)	  After	  passaging,	  most	  cells	  have	  a	  neuronal	  morphology.	   (H,	  H’)	  By	  Day	  30,	   cultures	  
contain	   a	   high	   percentage	   of	   cells	  with	   neuronal	  morphology	   but	  may	   also	   have	   some	   cell-­‐dense	  
regions.	  It	  is	  advisable	  to	  re-­‐plate	  cultures	  again	  at	  this	  time	  point	  to	  purify	  cell	  types	  of	  interest	  and	  
decrease	  cell	  density	  to	  ensure	  that	  neurons	  receive	  adequate	  nutrients.	  (I,	  I’)	  Culture	  morphology	  at	  
Day	  31	  after	  re-­‐plating	  at	  1x105	  cells	  per	  cm2.	  (J,	  J’)	  Cellular	  morphology	  of	  Day	  60	  cultures	  re-­‐plated	  
at	  1x105	  cells	  per	  cm2	  on	  Day	  30.	  Abbreviations:	  12-­‐wp,	  12	  well	  plate;	  24-­‐wp,	  24	  well	  plate;	  96-­‐wp,	  96	  
well	  plate.	  
	  
	   	  
	  
	  
Figure	   3:	   Quality	   control	   of	   hPSC	   hypothalamic	   differentiations	   by	   immunocytochemistry.	   (A)	  
Immunofluorescent	  staining	  on	  Day	  10	  of	  hES	  cells	  differentiated	  to	  dorsal	  forebrain	  (cortical)	  cells.	  
The	  vast	  majority	  of	  cells	  in	  these	  cultures	  express	  the	  transcription	  factor	  FOXG1	  that	  is	  expressed	  in	  
the	  telencephalon	  in	  vivo,	  and	  few	  cells	  expressing	  the	  transcription	  factor	  NKX2.1	  that	  is	  expressed	  
in	  the	  ventral	  forebrain.	  DNA	  is	  stained	  with	  DAPI	  to	  visualise	  cell	  nuclei.	  (B)	  On	  Day	  10	  of	  hypothalamic	  
differentiation,	  the	  vast	  majority	  of	  cells	  express	  NKX2.1,	  and	  only	  a	  few	  express	  FOXG1.	  (C)	  On	  Day	  
24	  of	  hypothalamic	  differentiation,	  some	  hPSC-­‐derived	  cells	  express	  POMC	  and	  many	  cells	  express	  
microtubule-­‐associated	  protein	  2	  (MAP2),	  a	  dendritic	  marker	  indicative	  of	  neuronal	  identity.	  (D,E)	  On	  
Day	   119	   of	   differentiation,	   hypothalamic	   cultures	   retain	   numerous	   neurons	   expressing	   POMC	  
(arrows),	  Agouti-­‐related	  peptide	  (AGRP)	  (arrowheads)	  and	  Hypocretin/orexin	  (HCRT)	  (arrowheads).	  	  
	  
	  Figure	  4:	  Calcium	  imaging	  of	  hPSC-­‐derived	  hypothalamic	  neurons.	  (A)	  Schematic	  showing	  Fura-­‐2AM	  
loading	  of	  neurons.	  Cells	  are	  incubated	  in	  333	  nM	  Fura-­‐2AM	  for	  45	  minutes	  in	  an	  incubator	  at	  37˚C.	  
After	  gently	  washing	  cultures	   twice	  with	  ACSF,	  cells	  are	   incubated	   for	  a	   further	  30	  minutes	  before	  
performing	  the	  imaging.	  (B)	  A	  typical	  field	  of	  Fura-­‐2AM-­‐loaded	  hypothalamic	  neurons	  at	  Day	  77	  post-­‐
differentiation	  with	  cells	  of	  interest	  highlighted	  (1,	  2	  and	  3).	  (C)	  Trace	  of	  the	  340	  nm	  /	  380	  nm	  intensity	  
ratio	  over	  time	  in	  the	  three	  cells	  highlighted	  in	  (B),	  showing	  a	  depolarisation	  in	  the	  cells	  after	  perfusion	  
of	  an	  exogenous	  compound	  and	  a	  large	  depolarisation	  when	  perfused	  with	  ACSF	  containing	  30	  mM	  
potassium	  chloride	  (KCl).	  (D)	  Spontaneous	  calcium	  transients	  in	  the	  absence	  of	  stimulation.	  
